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Primary cutaneous t-cell lymPhomas
Primary cutaneous lymphomas represent a heterogeneous group of malignant non-hodgkin 
lymphomas that clinically originate in the skin with no evidence of extracutaneous disease at the 
time of diagnosis. the incidence is being estimated on 1:100,000 individuals per year.1 Primary 
cutaneous lymphomas often differ in clinical behavior, prognosis and biological features from 
their histologically similar nodal counterparts with or without secondary skin involvement, 
indicating a different pathogenesis and requiring a different treatment.2 For these reasons, 
primary cutaneous lymphomas were included as distinct entities in recent classifications for 
malignant lymphomas (eortc 1997; Who-eortc 2005; Who 2008).2-4 two main categories 
can be distinguished: primary cutaneous t-cell lymphomas (ctcl), accounting for 75-80% of 
cases and primary cutaneous B-cell lymphomas (cBcl), accounting for 20-25% of cases. Within 
the group of ctcls three subgroups can be distinguished: (1) the group of classical ctcls, 
including mycosis fungoides (mF), variants of mF, and sézary syndrome (ss); (2) the group of 
primary cutaneous cD30-positive lymphoproliferative disorders (cD30+ lPD); and (3) a group 
of rare and often aggressive cutaneous t/nK-cell lymphomas. table 1 shows the Who-eortc 
classification and relative frequencies of most cutaneous lymphomas. the studies in this thesis 
focused on cutaneous cD30-positive lymphoproliferations, in particular primary cutaneous 
anaplastic large cell lymphoma (c-alcl). as c-alcl is part of the group of primary cutaneous 
Table 1. Who-eortc classification for cutaneous lymphomas
Frequency  
(%)*
5-yr DSS  
(%)
Cutaneous T-cell lymphoma 
     mycosis fungoides (variants) 48 88-100
     sézary syndrome 3 24
     Primary cutaneous cD30+ lymphoproliferative disorders
         Primary cutaneous anaplastic large cell lymphoma





     subcutaneous panniculitis-like t-cell lymphoma 1 82
     Primary cutaneous nK/t-cell lymphoma, nasal type <1 nr
     Primary cutaneous cD4+ small/medium pleomorphic t-cell lymphoma 2 75
     Primary cutaneous aggressive cD8+ t-cell lymphoma <1 18
     Primary cutaneous γ/δ t-cell lymphoma <1 nr
     Primary cutaneous peripheral t-cell lymphoma, not otherwise specified 2 16
Cutaneous B-cell lymphoma 
    Primary cutaneous marginal zone B-cell lymphoma 7 99
    Primary cutaneous follicle centre lymphoma 11 95
    Primary cutaneous large B-cell lymphoma, leg type 4 55
*Data are based on 1905 patients with a primary cutaneous lymphoma registered by the Dutch and austrian 




CD30+ LPD, this introductory chapter focuses on the clinical aspects, differential diagnosis and 
molecular aspects involved in the pathogenesis of this subgroup of CtCL.
CD30 
In 1982, Schwab et al. described a new molecule that was initially termed Ki-1 and subsequently 
designated CD30.5 CD30 is a 120-kDa transmembrane cytokine receptor of the tumor necrosis 
factor receptor family, located on chromosome 1p36.6;7 Interaction between CD30 and its natural 
ligand CD30L (CD153, located on chromosome 9q33), which is expressed constitutively by 
granulocytes, activated t-cells and histiocytes, results in pleiotropic effects depending on cell 
type, state of differentiation or activation and the presence of other stimuli.8 the CD30 antibody 
was first reported to react selectively with Hodgkin and Reed-Sternberg cells in Hodgkin’s 
disease and with scattered activated blast cells in the perifollicular areas in reactive lymph 
nodes and tonsils.9 Further studies showed that CD30 was also expressed by highly activated 
B- and t-cells and by a group of diffuse large cell lymphomas, which generally show a t- or 
null-cell phenotype and sometimes a B-cell phenotype.10 Because of constant CD30 expression 
and frequent anaplastic features, these lymphomas were accepted as a distinct morphologic 
entity, initially called Ki-1 or CD30-positive (large cell) lymphoma and later anaplastic large 
cell lymphoma (ALCL).11 In addition, a primary cutaneous variant was recognized (C-ALCL), 
and it was found that the large atypical cells in skin biopsies of lymphomatoid papulosis 
(LyP) also express the CD30 molecule.12;13 Because of the overlapping clinical, histological and 
immunophenoptypical features, it was then suggested that C-ALCL and LyP are parts of a 
spectrum of primary cutaneous CD30+ LPD.14
tHe GROUP OF PRIMARy CUtANeOUS CD30-POSItIVe 
LyMPHOPROLIFeRAtIVe DISORDeRS
Primary cutaneous CD30+ LPD represent the second most common subgroup of CtCL, 
accounting for approximately 25% of all CtCL (table 2). this group includes C-ALCL, LyP 
and borderline cases.2 C-ALCL is composed of large cells with anaplastic, pleomorphic, or 
immunoblastic cytomorphology and expression of the CD30 molecule by more than 75% of 
the tumor cells and without clinical evidence or history of MF, or another type of CtCL. LyP 
is defined as a chronic, recurrent, self-healing papulonecrotic or papulonodular skin disease 
with histologic features suggestive of a (CD30+) malignant lymphoma. As both disorders show 
overlapping clinical, histological and immunophenotypical features the clinical appearance 
and course are used as decisive criteria for the definitive diagnosis and choice of treatment. 
the main clinical characteristics are summarized in table 2. the term ‘borderline cases’ was 
initially used for cases with a discrepancy between the clinical features and the histological 
appearance.14 Nowadays it refers to cases in which, despite careful clinicopathologic correlation, 
a definite distinction between C-ALCL and LyP cannot be made yet. Clinical examination during 





Primary cutaneous anaplastic large cell lymphoma 
the median age of C-ALCL patients is around 60 years with a male to female ratio of 2-3:1.15;16 
Most patients present with solitary or localized nodules or tumors, and sometimes papules, 
often showing ulceration (Figure 1). Multifocal lesions are seen in about 20% of the patients. 
In about 40% of the cases, the skin may show partial or complete spontaneous regression.15 
Skin relapses occur frequently, but extracutaneous dissemination is uncommon.15;16 Prognosis 
is usually favorable with a 10-year disease-specific survival of approximately 90%.15-17 Risk 
factors that predict an unfavorable course, occurring in few patients with C-ALCL, are largely 
unknown. However, several studies have suggested that age older than 60 years, absence 
of spontaneous remission, and presentation with multifocal skin lesions may correlate with 
reduced survival.15;18-20 Moreover, extensive single limb involvement and localization on the 
head and neck have been associated with a less favorable prognosis.16;21;22 In chapter 2 we 
investigated the prognostic significance of a large number of parameters including sex, age 
(≤60 vs. >60 years), extent of disease, site of presentation, and complete spontaneous remission 
of initial skin lesions in a large group of patients (n=135) with C-ALCL. For extent of disease we 
used the recently described tNM classification system for primary cutaneous lymphomas other 
than MF and SS, as proposed by the International Society for Cutaneous Lymphomas (ISCL) and 
Cutaneous Lymphoma task Force (CLtF) of the eORtC.23 this classification system is meant to 
replace the use of the Ann Arbor system, which is the primary means for classifying the extent 
of disease in patients with non-Hodgkin lymphomas. this, because the Ann Arbor system has 
a number of shortcomings for lymphomas that arise primarily in extranodal sites such as the 
skin. For instance, in primary cutaneous lymphomas, the initial stage according to the Ann 
Arbor system would either be Ie (if single skin site) or IVD + (if multiple skin sites), thereby 
disproportionally or inappropriately placing many patients in the highest stage, resulting in 
unnecessarily aggressive treatments.23 A major goal of the study described in chapter 2 was to 
investigate the applicability and prognostic value of this new tNM classification system.
Table 2.
C-ALCL LyP






therapy excision/Rt None (MtX/Rt)
Risk to develop systemic disease at 10 years 16% 4%
Disease related 10-year-survival >90% 100%





LyP generally occurs in adults, but may occur in children as well.15;16 the median age is around 
45 years with a male to female ratio of 1.5-2:1. Most patients present with generalized papular, 
papulonecrotic, and/or nodular skin lesions at different stages of development, predominantly 
on the trunk and limbs (Figure 1).15;16;20 Individual skin lesions disappear within 3-12 weeks, and 
may leave behind superficial scars. the duration of the disease may vary from several months 
to more than 40 years.2 LyP has an excellent prognosis. In up to 20% it may be preceded by, 
associated with, or followed by another type of malignant (cutaneous) lymphoma, generally 
MF, (C-)ALCL, or Hodgkin lymphoma.15 Risk factors that identify patients most likely to develop 
another type of malignant (cutaneous) lymphoma or extracutaneous disease are not known. 
Histologic features
Primary cutaneous anaplastic large cell lymphoma
C-ALCL show diffuse nonepidermotropic infiltrates with cohesive sheets of large CD30+ 
tumor cells (Figure 1).11;14 In most cases, the tumor cells have the characteristic morphology 
of anaplastic cells, with round, oval, or irregularly-shaped nuclei, prominent (eosinophilic) 
nucleoli, and abundant cytoplasm. Less commonly (20-25%), they have a nonanaplastic 
(pleomorphic or immunoblastic) appearance. Reactive lymphocytes are often present at the 
periphery of the lesions. Ulcerating lesions may show a LyP-like (type A) histology with an 
abundant inflammatory infiltrate of reactive t-cells, histiocytes, eosinophils, neutrophils, and 
few CD30-positive cells.
Lymphomatoid papulosis
the histologic picture of LyP is extremely variable and in part correlates with the age of the 
biopsied skin lesion. Four histologic subtypes (types A, B, C, and D) have been described.11;24;25 
In LyP type A lesions, scattered or small clusters of large, sometimes multinucleated or Reed-
Sternberg-like, CD30+ cells are intermingled with numerous inflammatory cells, such as 
histiocytes, small lymphocytes, neutrophils, and/or eosinophils (Figure 1). LyP type C lesions 
demonstrate a monotonous population or large clusters of large CD30+ t-cells with relatively 
few admixed inflammatory cells. LyP type B is uncommon (less than 10%) and is characterized by 
an epidermotropic infiltrate of small CD4+, CD30- atypical cells with cerebriform nuclei similar 
to that observed in MF. LyP type D consists of an epidermotropic infiltrate of small- to medium-
sized CD8+ and CD30+ atypical lymphoid cells that histologically resembles primary cutaneous 
aggressive epidermotropic CD8+ cytotoxic t-cell lymphoma.24 Recognition of the different 
histologic subtypes of LyP has contributed to a better definition and to a better understanding 
of the relationship between LyP and other types of CtCL. However, from a clinical point of view, 
differentiation between these different subtypes is not useful, as they do not differ clinically.
Immunophenotype
except for LyP type B, which are generally CD30 negative, CD30+ LPD show CD30 staining 
on the cell membrane and in the Golgi region of most of the neoplastic cells.18 In most 
cases these neoplastic cells have an activated CD4+ t-cell phenotype with variable loss of 




proteins).13;26 Some cases have a CD8+ t-cell phenotype. Most primary cutaneous CD30+ LPD 
express the cutaneous lymphocyte antigen (CLA), but do not express epithelial membrane 
antigen (eMA) and anaplastic lymphoma kinase (ALK), indicative of the 2;5 chromosomal 
translocation or its variants in systemic ALCL.27;28 Recent studies have reported on the utility 
of immunohistochemical markers to differentiate between C-ALCL and LyP, such as BCL2, 
clusterin, tNF-receptor associated factor 1 (tRAF1) and IFN regulatory factor 4 (IRF4; also known 
as multiple myeloma antigen 1 or MUM1)29-32. the results of these studies are often unconfirmed 
or conflicting. Chapter 3 evaluates the value of some of these phenotypical markers in a large 
group of cutaneous CD30+ lymphoproliferations.
Genetic features
Clonally rearranged t-cell receptor genes have been detected in nearly all C-ALCL and 
approximately 60%-70% of LyP lesions.33;34 Identical rearrangements have been demonstrated 
in LyP lesions and associated lymphomas.35;36
Figure 1. A: Clinical example of C-ALCL; B: clinical example of LyP; C: cohesive sheets of large CD30+ 
tumor cells, suggestive for a C-ALCL lesion; D: scattered CD30+ large tumor cells, suggesting LyP, 
type A; However, the histologic picture in panel C and D can be found both in C-ALCL and in LyP. the 
final diagnosis depends therefore on the clinical presentation.
 7 
Table 2. 
 C-ALCL LyP 
Extent skin lesions Solitary/localized Generalized 
Spontaneous remission 20% complete 
20% partial 
100% 
Staging Yes No 
Therapy Excision/RT None (MTX) 
Risk to develop systemic disease at 10 years 16% 4% 
Disease related 10-year-survival >90% 100% 
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the translocation t(2;5) (p23;q35) resulting in expression of NPM-ALK protein (p80), which 
is predominantly found in systemic ALCL in children, is not or rarely found in LyP and C-ALCL.27 
Recently, a new translocation involving the IRF4 gene locus has been discovered in 20-25% of 
C-ALCL cases. 24;37;38 In other CtCL this translocation has been rarely found. 
the results of recent studies employing array-based comparative genomic hybridization 
(aCGH) and gene expression profiling are described in the following paragraph.
etiology and pathogenesis
the mechanisms that are involved in the development of primary cutaneous CD30+ LPD 
are largely unknown.11 So far, no causative agent has been identified. Because viral antigens 
may strongly induce CD30 expression in t-and B-cells, a viral etiology has been suggested. 
However, studies for an etiologic role of human t-lymphotrophic virus-1, epstein-Barr virus 
(eBV) and other herpes viruses, including herpes simplex virus (HSV) type 1 and type 2 and 
human herpesvirus-6, 7, and 8, have been consistently negative.39-42 
Spontaneous remission is one of the most characteristic features of these CD30-positive 
lymphomas and occurs, by definition, in all patients with LyP and in approximately 40% of cases 
of C-ALCL15. Several studies have investigated the expression of apoptosis related proteins that 
may contribute to the spontaneous disappearance of skin lesions. For instance, it was shown that 
the FAS receptor is consistently expressed by CD30+ LPD tumor cells, in contrast to aggressive 
types of CtCL.43;44 In addition, lower levels of the antiapoptotic protein BCL2 were found in LyP 
compared with nonregressing lesions of C-ALCL suggesting that increased BCL2 expression in 
nonregressing lesions of C-ALCL protects tumour cells from apoptosis.44 It was also suggested 
that interactions between CD30 and CD30L may contribute to apoptosis of the neoplastic 
t-cells.45 However, the exact mechanisms responsible for the regression of skin lesions are still 
unknown. Regarding possible mechanisms for tumor progression, unresponsiveness to the 
growth inhibitory effects of transforming growth factor-beta (tGF-beta) by point mutations 
and deletions in the tGF-beta type I and type II receptors46;47, as well as high levels of BCL2 
expression by the CD30-positive tumor cells44 have been suggested. 
Recent studies have shed light on molecular (epi)genetic features of C-ALCL. Using aCGH 
analysis van Kester et al. identified several recurrent copy number alterations including gains on 
chromosome 7q and 17q and losses on 6q and 13q.48 Nearly identical results were found in a recent 
study by Laharanne et al., using a different aCGH platform.49 In both studies the 9p21 deletion 
(involving the CDKN2A-CDKN2B gene locus) was rare or absent in C-ALCL patients, which is in 
contrast to patients with transformed mycosis fungoides (MF-tR).48-51 In the same study by van 
Kester et al. gene expression profiling showed increased expression of skin-homing chemokine 
receptors compared to cutaneous peripheral t-cell lymphoma, not otherwise specified (PtL-
NOS), which may contribute to the lower tendency to disseminate to extracutaneous sites.48 
Additionally, based on the increased expression of CD30, tRAF1 and IRF4 Wozniak and Piris 
speculate that CD30-mediated NF-κB activation may play a role in the pathogenesis of C-ALCL.48;52
On the epigenetic level van Doorn et al. found that BCL7a was hypermethylated at a lower 
frequency in C-ALCL (14%) compared to aggressive types of CtCL (64%). they suggested that this 
gene functions as a tumor suppressor in lymphoid cells.53 Little is known about histon modifications 




Several studies have demonstrated specific miRNA expression profiles in different types of CTCL 
suggesting a role in the pathogenesis of these disorders. In chapter 5 we investigated the miRNA 
expression profile of C-ALCL and compared the results with tumor stage MF. 
Differential diagnosis
CD30 is not only expressed by the conditions included in the group of primary cutaneous 
CD30+ LPD, but also by systemic anaplastic large cell lymphoma involving the skin secondarily, 
MF-TR, certain other lymphomas and reactive skin conditions, which may mimic CD30+ LPD 
histologically (Table 3).
Secondary cutaneous anaplastic large cell lymphomas 
Two types of systemic ALCL are included as separate entities in the WHO 2008 classification: 
ALK+ and ALK- ALCL.4 ALK+ ALCL is associated with the t(2;5) translocation resulting in expression 
of the anaplastic large cell lymphoma kinase (ALK) protein. ALK+ ALCL occur most frequently 
in the first three decades of life and often involve both lymph nodes and extranodal sites such 
as skin.54 It has a relatively good prognosis with a 5-year overall survival of approximately 80%.55 
Extranodal sites are less commonly involved in ALK- ALCL, but can include skin as well. Patients 
with ALK- ALCL have a higher median age than ALK+ ALCL and their survival is significantly 
worse with an overall 5-year survival rate of only 46%.55 
In order to differentiate between a primary and secondary cutaneous ALCL adequate staging 
investigations have to be performed. According to guidelines from the Dutch Cutaneous 
Lymphoma Group (DCLG), this staging work-up should include physical examination, 
laboratory studies, imaging studies and a bone marrow biopsy. However, recent data from the 
registry of the DCLG show that in an increasing number of patients with an ALCL presenting in 
the skin, in particular those presenting with a solitary tumor that has resolved spontaneously 
Table 3 .Differential diagnosis of cutaneous CD30+ lymphoproliferations
Primary cutaneous CD30+ lymphoproliferative disorders
 • Primary cutaneous anaplastic large cell lymphoma
 • Lymphomatoid papulosis
 • Borderline cases
Transformed mycosis fungoides
Systemic ALCL with secondary skin involvement
Other lymphomas
 •  Other CTCL that sometimes express CD30: epidermotropic CD8+ CTCL, pagetoid reticulosis, 
patch or plaque stage MF
 • CD30+ cutaneous B-cell lymphomas: e.g. posttransplant (EBV+) LPD, MTX-associated lymphomas
 • Hodgkin lymphoma with secondary skin involvement
Reactive skin conditions
 • Atopic dermatitis
 • Drug reactions
 • Viral infections: Milker’s nodule, HIV, HSV or VZV infections, molluscum contagiosum
 • Persistent arthropod bite reactions




or has been excised completely, staging is incomplete and particularly a bone marrow biopsy 
is not always performed. Moreover, the recently published classification system for non-MF/SS 
primary cutaneous lymphomas suggests that in cutaneous lymphomas with an indolent clinical 
behavior such as C-ALCL, bone marrow evaluation should be considered, but is not required, 
unless indicated by other staging assessments.23 In chapter 4 we investigated whether the 
current policy to advice bone marrow examination in all patients with C-ALCL should be 
maintained or whether it should be performed only in selected cases.
Transformed mycosis fungoides
MF is the most common type of CtCL (table 1), clinically characterized by the slow progression 
from patches to plaques and in a proportion of patients to tumors and development of 
extracutaneous disease.2 Histologically, the early stages of MF show superficial band-like 
or lichenoid infiltrates with atypical small- to medium-sized t-cells with highly indented 
(cerebriform) nuclei into the epidermis (epidermotropism). With progression to tumor stage, 
the dermal infiltrates become more diffuse, with an increase in the proportion of tumor cells 
as well as an increase in the number of blast cells, and epidermotropism may get lost. While 
patients with early patch or plaque stage MF generally run an indolent course with a 10-year 
DSS over 80%, patients developing skin tumors or extracutaneous disease have a reduced 
10-year DSS of 42% and <20%, respectively.56 Apart from clinical stage, large cell transformation 
(LCt) has been associated with an aggressive clinical course and a poor survival. LCt is defined 
by the presence of large t cells exceeding 25% of the total lymphoid infiltrate or forming 
microscopic nodules. these large t-cells may be CD30+ or CD30-. In view of the excellent 
prognosis of C-ALCL (CD30+), several studies have evaluated whether CD30 expression in 
MF-tR is associated with a good survival as well.57-59 However, in none of the published studies 
a significant difference between CD30+ and CD30- cases was found, probably because of the 
small size of the study groups. evaluation of studies to prognostic factors in MF-tR is further 
hampered by the inclusion of not only patients with MF but also variable numbers of patients 
with SS and by variable proportions of patients with LCt at extracutaneous sites. to find out 
whether CD30 expression and other prognostic factors are related to a better survival of 
patients with MF-tR, we have evaluated clinicopathologic and immunophenotypical data in a 
large group of patients. the results are presented in chapter 6.
Other lymphomas
Other types of cutaneous lymphoma that may express CD30 can be divided in three groups: (1) 
well-defined types of CtCL that sometimes express the CD30 antigen including CD8-positive 
epidermotropic CtCL60, pagetoid reticulosis61 and rare cases of patch or plaque stage MF; (2) 
skin localizations of CD30+ B-cell lymphomas, such as (eBV positive) posttransplant LPD or MtX 
associated lymphoma and (3) classical Hodgkin lymphoma with secondary skin involvement.4
Reactive skin conditions
Increasing numbers of benign skin conditions are being identified, in which the reactive 
inflammatory infiltrate may contain scattered or sometimes large clusters of large CD30+ t-cells, 
which mimic LyP or C-ALCL histologically. these include atopic dermatitis, lymphomatoid drug 




varicella zoster virus (VZV) infections, molluscum contagiosum), persistent arthropod bite 
reactions and pseudolymphoma (table 2). 
treatment
treatment of CD30+ LPD should primarily be based on the size, the extent, and the clinical 
behavior of the skin lesions.15 In LyP, one should take into account that a curative therapy is not 
available and that none of the available treatment modalities affects the natural course of the 
disease. For that reason, the short term benefits of active treatment should be balanced carefully 
against the potential side effects. For patients with few non-scarring lesions active treatment 
is not necessary. For patients with numerous, disseminated, or stigmatizing lesions, low-dose 
methotrexate (5-25 mg/week) and phototherapy, in particular PUVA, are preferred options.62 
Solitary or localized C-ALCL are usually treated with surgical excision or radiotherapy.15;62 
the preferred type of treatment in patients with multifocal skin lesions has been subject of 
debate. For a long time, multiagent chemotherapy has been used as first-line therapy in patients 
with multifocal skin lesions. However, skin relapses are common. In recent eORtC, ISCL and 
United States Cutaneous Lymphoma Consortium consensus recommendations multiagent 
chemotherapy is therefore only advised in patients developing extracutaneous disease.15;62 
For multifocal skin lesions low-dose Methotrexate (5-25 mg/week), as in LyP, is suggested. 
Alternatively, retinoids or interferon can be considered.
AIM AND OUtLINe OF tHe tHeSIS 
the studies presented in this thesis have aimed to address questions regarding clinical aspects, 
differential diagnosis and molecular aspects involved in the pathogenesis of cutaneous CD30+ 
lymphoproliferations.
Chapter 2 evaluates the applicability and prognostic value of the new tNM classification 
system for primary cutaneous lymphomas other than MF and SS in patients with C-ALCL and 
investigates the prognostic significance of other clinical variables.
Chapter 3 analyses the diagnostic and prognostic value of phenotypic markers tRAF1, 
MUM1, BCL2 and CD15 in several cutaneous CD30-positive lymphoproliferations including 
C-ALCL, LyP, CD30+ MF-tR and skin localizations of systemic ALCL.
Chapter 4 evaluates the current policy to advice bone marrow examination to patients with 
an ALCL presenting in the skin.
Chapter 5 provides an analysis of the miRNA expression profiles of skin biopsies from 
C-ALCL patients compared to skin biopsies from patients with benign inflammatory dermatoses 
and tumor stage MF.
Chapter 6 retrospectively analyses prognostic factors in patients with MF-tR and provides 
a prognostic index. 
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Objectives: to test the applicability and prognostic value of the new tNM classification system 
for primary cutaneous lymphomas other than mycosis fungoides and sézary syndrome in 
patients with primary cutaneous anaplastic large cell lymphoma (c-ALcL) and to evaluate the 
prognostic significance of other clinical parameters, in particular the site of presentation.  
Design: retrospective cohort analysis.
Setting: Dutch cutaneous Lymphoma Group database.
Patients: One hundred thirty-five patients with c-ALcL.
Main Outcome Measures: clinical variables, including t category and site of presentation. 
Results: Eighty patients (59.3%) presented with t1 disease, 37 (27.4%) with t2 disease and 18 
(13.3%) with t3 disease. Median follow-up was 56 months (range, 11-288 months). Five-year 
disease-specific survival (Dss) was 93% for t1 disease, 93% for t2 disease, and 77% for t3 disease 
(P=.19). Patients with skin lesions on a leg had a reduced 5-year Dss compared with lesion on 
other sites (82% for leg vs 95% for head and neck, 96% for trunk,  and 95% for arm; p=0.23). 
Patients with leg involvement (n=32) had significantly worse 5-year Dss than did patients 
without leg involvement (n=103; 76% vs 96%; P=.03 after adjustment for t-category).
Conclusions: the new tNM system can be applied well to patients with c-ALcL and may provide 
prognostic information, in particular, P when combined with site of presentation. Patients with 
t2 or t3 disease with skin lesions on the leg may have a reduced survival and require close 
surveillance during follow-up.




Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a non-Hodgkin lymphoma of 
t-cell origin that presents in the skin without evidence of extracutaneous disease at the time 
of diagnosis. It is characterized by large cells with an anaplastic, pleomorphic or immunoblastic 
cytomorphology and expression of the CD30 antigen by more than 75% of the tumor cells.1 
Patients with C-ALCL show overlapping clinical, histological and immunophenotypical 
features with lymphomatoid papulosis (LyP) that together form a spectrum of disease, 
collectively designed as primary cutaneous CD30-positive lymphoproliferative disorders.2 
Distinction between C-ALCL and LyP is based on a combination of clinical, histological and 
immunophenotypical criteria.3 C-ALCL is regarded as an indolent type of cutaneous t-cell 
lymphoma (CtCL), as illustrated by several large studies3-5 showing 10-year disease-specific 
survival (DSS) of approximately 90% and 10-year overall survival (OS) of approximately 75%. Risk 
factors that predict an unfavorable course, occurring in few patients with C-ALCL, are largely 
unknown. However, several studies3,6-8 have suggested that ages older than 60 years, absence 
of spontaneous remission, and presentation with multifocal skin lesions may correlate with 
reduced survival. Moreover, extensive single-limb involvement and localization on the head 
and neck have been associated with a less favorable prognosis.4,9
Recently, a new tNM classification system has been developed for primary cutaneous 
lymphomas other than mycosis fungoides (MF) and Sézary syndrome (SS). this classification 
system is primarily meant to document extent of disease in a consistent manner, facilitating 
comparison of studies at different institutes (table 1).10  Recent studies11-13 have started to 
evaluate the clinical usefulness of this tNM system. Studies of large groups of cutaneous 
B-cell lymphomas confirmed its applicability and suggested that this system has prognostic 
significance in primary cutaneous diffuse large B-cell lymphomas, leg type, but not in primary 
cutaneous follicle centre lymphomas and primary cutaneous marginal zone lymphomas. 
However, studies in CtCL other than MF and SS, have not been published thus far. 
the aim of the present study was to test the applicability and prognostic value of this tNM 
classification system for C-ALCL. In addition, the prognostic significance of other clinical 
parameters, in particular the site of presentation, was evaluated.  
MetHODS
Patients
Between January 1, 1986, and December 31, 2007, 155 patients with C-ALCL had been included 
in the database of the Dutch Cutaneous Lymphoma Group, and follow-up data were collected 
yearly for each patient. All of the cases were reviewed by an expert panel of dermatologists 
and hematopathologists before entry in this database. All of the cases met the criteria of the 
World Health Organization-european Organization for Research and treatment of Cancer 
classification, and none of them had evidence of extracutaneous disease at the time of diagnosis.1 
Patients with a follow-up of less than 12 months, unless they died of their lymphoma (n=17), 
and patients with human immunodeficiency virus-associated (n=2) or posttransplantation 
(n=1) ALCL were excluded. Six patients with skin lesions suggesting C-ALCL but who developed 
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characteristic skin lesions of MF during follow-up were excluded because a diagnosis of 
transformed MF was considered more likely. the final study group contained 135 patients. 
Seventy-nine of these 135 patients were included in a previous study3  that aimed to define 
guidelines for diagnosis, management and treatment for this group of cutaneous lymphomas. 
this study was approved by the Medical ethical Committee of the Leiden University Medical 
Center, Leiden, the Netherlands.
Assessment of clinical variables (including t category)
In all of the patients, the following clinical parameters were scored retrospectively: sex, age 
at diagnosis, site of presentation, extent of disease at presentation, spontaneous remission of 
initial skin lesions, type and result of initial therapy, occurrence and site of relapse, disease-free 
survival after complete remission (in months), duration of follow-up (in months) and current 
status. extent of disease was scored using the proposed tNM classification system for primary 
cutaneous lymphomas other than MF and SS (table 1). Because patients with C-ALCL have, by 
definition, no extracutaneous disease (lymph node or visceral) at the time of diagnosis, only t 
categories were scored. 
Statistical analysis
Statistical analysis was performed using SPSS 16.0 (SPSS Inc, Chicago, Illinois). Rates of DSS and 
OS were calculated from date of diagnosis until death from lymphoma and death from any 
Table 1. Classification and description of the proposed tNM classification system for cutaneous lymphomas 
other than mycosis fungoides and Sézary syndrome10
Classification Description
t1 Solitary skin involvement.
t1a: Solitary lesion ≤ 5 cm in diameter
t1b: Solitary lesion > 5 cm in diameter
t2 Regional involvement of skin: multiple lesions limited to 1 body region or 2 
contiguous body regions.
t2a: All-disease-encompassing in a ≤ 15 cm diameter circular area
t2b: All-disease-encompassing in > 15 and ≤ 30 cm diameter circular area
t2c: All-disease-encompassing in a > 30 cm diameter circular area
t3 Generalized skin involvement.
t3a: Multiple lesions involving two noncontiguous body regions
t3b: Multiple lesions involving ≥ 3 body regions
N0 No clinical or pathologic involvement of lymph node
N1 Involvement of one peripheral lymph node region that drains an area of current or 
prior skin involvement
N2 Involvement of ≥ 2 peripheral lymph node regions or involvement of any lymph 
node region that does not drain an area of current or prior skin involvement
N3 Involvement of central lymph nodes
M0 No evidence of extracutaneous non-lymph node disease
M1 extracutaneous non-lymph node disease present
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cause, respectively, or last follow-up without an event. Survival curves were estimated using the 
Kaplan-Meier technique, and comparison between curves was performed using the log-rank test. 
Prognostic factors were evaluated by means of univariate and multivariate analysis with OS and DSS 
as end points, and P<0.05 were considered significant. Clinical parameters included for univariate 
analysis were sex, age (≤ 60 vs. > 60 years), extent of disease (t category), site of presentation, and 
complete spontaneous remission of initial skin lesions. Multivariate analysis was performed using 
significant univariate variables from the Cox proportional hazards regression analysis.
ReSULtS
Clinical characteristics at diagnosis, type of initial treatment and follow-up data are provided 
in table 2. the study group included 97 males (71.9%) and 38 females (28.1%), with a median 
age at diagnosis of 61 years (range, 8-89 years). Using the tNM system, 80 patients initially 
had a solitary skin lesion (t1), 37 had regional skin lesions (t2), and only 18 had generalized skin 
lesions (t3). Representative examples are presented in Figure 1. 
Figure 1. examples of different t categories in patients with C-ALCL. examples of different t categories 
in patients with C-ALCL: A, t1a; B, t1b; C, t2a; D t2b; e and F, t3b (skin lesions on trunk not shown).
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Table 2. Clinical characteristics at diagnosis, type of initial treatment and follow-up data of 135 patients 
with C-ALCL
Variable Value
Sex*   Male
   Female
97 (71.9)
38 (28.1)
Median age (range) 61 (8-89)
Extent of disease*  T1 (solitary skin lesion)
   T2 (regional skin lesions)




Site of skin involvement* Head/neck
   Trunk (incl. buttock)
   Arm
   Leg






Spontaneous remission of initial skin lesions*
   Absent
   Partial




Initial therapy*  Radiotherapy 
   Surgery
   None/topical steroids
   Multiagent chemotherapy
   Methotrexate
   PUVA








Results initial therapy* Complete remission
   Partial remission




Median disease free survival after initial therapy (range) 21 (1-182)
Occurrence and site of relapses*
   None
   Skin only





Median duration of follow-up (range) 56 (11-288)
Current status*  Alive without disease
   Alive with disease
   Death from lymphoma





Disease specific survival,% 5 y
   10 y
91
89
Overall survival,%  5 y
   10 y
80
71
Risk for extracutaneous disease,%
   5 y
   10 y
13
24
PUVA: psoralen-UV-A; *Data are given as number (percentage)
Applicability and prognostic value of the new TNM system in C-ALCL patients
2
28
The distribution of the different T categories and the subgroups within these main T 
categories, and the corresponding 5-year DSS and OS rates are given in Table 3. Solitary or 
regional skin lesions at presentation (T1 and T2 disease) were localized on the head and neck in 
42 patients (31.1%), on the trunk in 32 (23.7%), on a single arm in 22 (16.3%), and a single leg in 21 
(15.6%). Eighteen patients had generalized skin lesions (T3 disease). 
Initial therapy consisted of radiotherapy or excision in most patients (Table 2). Only 8 of 135 
patients had been treated with multiagent systemic chemotherapy initially. Twenty-three of 24 
patients with spontaneous remission had not received any treatment other than topical steroids in 
6 of them because of complete spontaneous remission of the skin lesions. During follow-up, none 
of these 24 patients, including 4 cases initially presenting with multifocal skin lesions, showed the 
waxing and waning of skin lesions typical of LyP, thus confirming a diagnosis of C-ALCL.
During follow-up 53 of 135 patients (39.3%) developed 1 or multiple cutaneous relapses, 
while 20 of 135 (14.8%) patients developed extracutaneous disease, including 10 patients 
with involvement of only peripheral lymph nodes draining an area of current or previous skin 
involvement and 10 with more extensive nodal or visceral disease. The median duration for 
development of extracutaneous disease was 18 months (range 2 to 125 months). Development 
of extracutaneous disease in these 20 patients was not associated with progression to a higher 
T category. After a median follow-up of 56 months (range, 11-288 months), 95 patients were 
alive without disease, 9 were alive with disease, 12 patients died of lymphoma, and 19 patients 
died from unrelated causes. Ten-year DSS was 89% and 10-year OS was 71%.
Prognostic parameters
Univariate analysis showed that sex, age (≤ 60 vs. > 60 years), extent of disease (T category), 
site of presentation, and complete spontaneous remission of initial skin lesions were not 
significantly related to survival. Multivariate analysis was, therefore, not performed. Regarding 
extent of disease, 5-year DSS for patients with T1disease was 93%, with T2 disease was 93%, 
and with T3 disease was 77%, indicating that patients with T3 disease have a reduced, although 
Table 3. Distribution of different T categories in 135 patients with C-ALCL 
T category No. (%) 5-year DSS (%) 5-year OS (%)
T1 80 (59.3) 93 85
   T1a 75 (55.6) 96 88
   T1b 5 (3.7) 60 40
T2 37 (27.4) 93 81
   T2a 24 (17.8) 96 86
   T2b 8 (5.9) 100 86
   T2c 5 (3.7) 80 60
T3 18 (13.3) 77 63
   T3a 7 (5.2) 83 71
   T3b 11 (8.1) 71 57
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statistically nonsignificant, survival rate compared with patients with t1 or t2 (P=.19) (table 3 
and Figure 2). Analysis of survival in different subgroups of t categories showed a significantly 
reduced 5-year DSS for patients with t1b vs t1a disease (60% vs 96%, P<0.001), but the number 
of patients (n=5) with t1b disease does not allow firm conclusions to be drawn. Subgroups of t2 
or t3 disease showed no significant differences in survival. 
Analysis of site showed a trend toward reduced 5-year DSS in patients presenting with skin 
lesions on a leg (82% for leg vs 95% for head and neck, 96% for trunk, and 95% for arm; P=0.23) 
(table 4). thus, in contrast to previous studies, 9  skin lesions on the head or neck were not 
associated with a less favorable prognosis. 
Further analysis showed that in patients with multifocal skin lesions (category t3), those with 
involvement of one (n=4) or both legs (n=7) had a 5-year DSS of 67% compared with 100% in 
Figure 2. Five-year disease-specific survival (DSS) for the different t categories in patients with 
cutaneous anaplastic large cell lymphoma
Table 4. Different sites of skin involvement in 135 patients with C-ALCL 
Site of skin involvement No. (%) 5-yr DSS (%) 5-yr OS (%)
Head 42 (31.1) 95 87
trunk 32 (23.7) 96 85
Arm 22 (16.3) 95 90
Leg 21 (15.6) 82 62
Generalized skin involvement
                    Legs involved
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Figure 3. Five-year disease-specific survival (DSS) of patients with cutaneous anaplastic large cell 
lymphoma with and without leg involvement
patients without leg involvement (P=0.20) (Table 4). Moreover, in the total study group, 5-year 
DSS of patients with leg involvement (n=32) and patients without leg involvement (n=103) were 
76% and 96%, respectively (P=0.007; after adjustment for T category, P=0.03 (Figure 3 and Table 5). 
COMMENT
In the present study the clinical usefulness of the new TNM classification system for primary 
cutaneous lymphomas other than MF and SS was tested on a group of 135 patients with a 
C-ALCL. Although primarily meant to document extent of disease in a consistent manner, we 
also evaluated the prognostic value of this classification system for this group of C-ALCL. The 
results of this study show that this new TNM system can be applied well on this group of CTCL. 
Five-year DSS in patients with T1 disease was 93%, with T2 disease was 93%, and with T3 disease 
Table 5. 5-year DSS in patients with and without leg involvement in different T categories 
T category No. (%)
Legs not involved (n=103) Legs  involved (n=32)
p-valueD+ (%) 5-yr DSS, % D+ 5-yr DSS, %
T1 80 (59.3) 4/70 (6) 94 1/10 (10) 90 0.39
T2 37 (27.4) 2/26 (8) 100 2/11 (18) 76 0.13
T3 18 (13.3) 0/7 100 3/11 (27) 67 0.20
Total group 135 (100) 6/103 (6) 96 6/32 (19) 76 0.03*
D+: patients who died from lymphoma/number of patients in each T category; *Adjusted  for T category
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was 77%, suggesting that patients with generalized skin lesions have a less favorable prognosis 
than do patients with solitary or localized skin lesions. Previous studies3,4,6 have also suggested a 
correlation with reduced survival in patients with multifocal skin lesions. In the group of 18 patients 
with generalized skin lesions (T3 disease), 3 of 11 with involvement of the legs died of lymphoma 
(all were patients with involvement of both legs), compared with none of the 7 patients without 
leg involvement (5-year DSS 67% vs 100%). Also, in the patients with regional skin lesions (T2 
disease), leg involvement was associated with reduced 5-year DSS (76% vs 100%4). In the total 
group of 135 patients, those with leg involvement had significantly worse survival than did those 
without leg involvement. These observations are in agreement with those of a previous study, 
which suggested that patients with extensive limb involvement are at risk for a poor prognosis.4 
The fact that in univariate analysis site of presentation was not statistically significantly related to 
survival can be explained by small sample sizes (Table 4). The same holds true when analyzing the 
association with survival for leg involvement within the 3 T categories separately (Table 5).
Apart from localization on the leg, presentation on the head and neck has also been 
associated with a less favorable prognosis.9 In the retrospective cohort analysis of 157 patients 
with solitary or localized C-ALCL retrieved from the Surveillance, Epidemiology, and End 
Results (SEER) database, patients with skin lesions on the head and neck showed a significantly 
increased risk of death. In contrast, in the present study, patients presenting with skin lesions 
on the head and neck had a 5-year DSS of 95%. Only one of 42 patients (2.4%) with a solitary 
skin lesion on the head andneck region died of lymphoma (56 months after diagnosis). These 
different results are difficult to explain. However, because diagnoses in the SEER database are 
not verified independently, it cannot be excluded that the SEER cohort contains several patients 
with folliculotropic MF. Such patients preferentially present at the head and neck region, 
commonly contain many CD30-positive blast cells, and have a worse prognosis than C-ALCL.14,15 
In conclusion, these results show that the new TNM system can be applied well to patients 
with C-ALCL and may provide prognostic information, in particular when combined with site of 
presentation. Patients with T2 and T3 disease with skin lesions on the leg were found to have a worse 
prognosis compared with patients without leg involvement. However, we do not believe that there 
is enough reason to adapt the current guidelines for the initial treatment of C-ALCL in these patients. 
These guidelines indicate that patients with solitary or localized skin lesions can best be treated with 
excision or radiotherapy, whereas in patients with multifocal skin lesions low-dose oral methotrexate 
or, in the case of few scattered skin lesions,  radiotherapy is preferred.3 However, patients with 
regional of generalized skin lesions that involve the leg should be controlled very closely and may 
require systemic chemotherapy in an earlier phase of disease progression. 
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Summary
Background: CD30 is expressed on various types of cutaneous lymphomas, including 
lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (C-aLCL), 
some cases of mycosis fungoides showing large cell transformation (mF-Tr) and skin 
localizations of systemic anaplastic lymphoma kinase (aLK)-positive or aLK-negative aLCL. 
Differentiation between these entities is often not possible on the basis of histology alone, but 
several markers, including TraF1, mum1 and BCL2, have been reported to provide additional 
diagnostic information. 
Objective: To evaluate the diagnostic and prognostic significance of these markers in a large 
group of cutaneous CD30-positive lymphoproliferations.
Methods: an immunohistochemical study on the expression of TraF1, mum1, BCL2 and CD15 
was performed on skin biopsies of 28 patients with C-aLCL, 39 patients with LyP, 11 patients with 
CD30-positive mF-Tr, two with aLK-positive aLCL and six with aLK-negative aLCL. In addition, 
the prognostic significance of these markers was evaluated.
Results: TraF1 was expressed in roughly 70-80%, and mum1 expression in 70-100% of all groups 
of cutaneous CD30-positive lymphoproliferations. Highest levels of BCL2 were expressed in 
mF-Tr (73%), in contrast to 21% in C-aLCL and 36% in LyP. Highest levels of CD15 were expressed in 
C-aLCL (44%), compared with 18% in LyP and 9% in mF-Tr. a relation with survival was not clear.
Conclusions: The results of the present study suggest that expression of TraF1, mum1, BCL2 
and CD15 can not be considered as useful diagnostic or prognostic makers in cutaneous CD30-
positive lymphoproliferations. Differentiation between these different conditions should be 
based on a combination of clinical, histological and immunophenotypical criteria.




Primary cutaneous CD30-positive lymphoproliferative disorders are the second most common 
group of cutaneous t-cell lymphoma (CtCL), accounting for 25-30% of all CtCL.1 this group 
includes primary cutaneous anaplastic large cell lymphoma (C-ALCL), lymphomatoid papulosis 
(LyP) and borderline cases. these conditions show overlapping clinical, histological and 
immunophenotypical features and are considered as a spectrum of disease. Consequently, 
differentiation between LyP and C-ALCL is often not possible on the basis of histological 
criteria alone.2 In addition, some cases of mycosis fungoides showing large cell transformation 
(MF-tR) and systemic ALCL involving the skin secondarily may show histological features 
indistinguishable from C-ALCL.1;3 Distinction between these different types of cutaneous CD30-
positive lymphoproliferations is however important, as they have a different clinical behaviour 
and require a different clinical approach. LyP is characterized by the presence of a chronic, 
recurrent, self-healing papulonodular skin eruption, rarely disseminates to extracutaneous 
sites and has an excellent prognosis with a 10-year disease-specific survival of 100%. therefore, 
staging is generally not required and most patients do not require any specific treatment. 
Most patients with C-ALCL present with solitary or localized skin lesions and have an excellent 
prognosis as well. However, a small proportion of C-ALCL may disseminate to extracutaneous 
sites and require systemic chemotherapy.2;4 In contrast to LyP patients, patients with C-ALCL 
should therefore be adequately staged. Systemic ALCL involving the skin secondarily includes 
cases associated with the t(2;5) translocation, resulting in strong expression of anaplastic 
lymphoma kinase (ALK) protein (ALK-positive ALCL), as well as cases which are ALK-negative.3;5 
Both groups should be treated with systemic chemotherapy and the prognosis is often poor. 
Also patients with MF showing histological transformation to a large cell lymphoma, which may 
be CD30-positive or CD30-negative, generally have an unfavourable clinical course.
In recent years several phenotypical markers, including tRAF1 [tumour necrosis factor (tNF) 
receptor-associated factor], MUM1 (multiple myeloma oncogene 1) and BCL2, have been reported 
as valuable diagnostic adjuncts that facilitate differentiation between the different groups of 
cutaneous CD30-positive lymphoproliferations.6-9 However, the results of these studies are often 
unconfirmed or conflicting. therefore, in this study we evaluated the diagnostic significance of 
these markers in a large group of CD30-positive lymphoproliferative disorders involving the skin. 
In addition, the prognostic significance of these markers, as well as CD15, was evaluated. 
MAteRIALS AND MetHODS
Patients
Paraffin-embedded skin biopsies of 27 patients with C-ALCL, 39 patients with LyP, 11 patients 
with CD30-positive MF-tR and eight patients with secondary cutaneous ALCL were available 
for this study. Skin biopsies from seven patients with a primary cutaneous peripheral t-cell 
lymphoma, not otherwise specified (PtL-NOS) and nine patients with plaque-stage MF, were 
included as a control group for tRAF1 and/or MUM1 staining. 
Information on all the patients was retrieved from the database of the Dutch Cutaneous 
Lymphoma Group (DCLG). the information had been reviewed by an expert panel of 
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dermatologists and hematopathologists before entry in this database, using criteria of the 
World Health Organization-european Organization for Research and treatment of Cancer 
(WHO-eORtC) classification for primary cutaneous lymphomas and the WHO classification 
for systemic lymphomas involving the skin secondarily.1;10 In all patients with C-ALCL routine 
staging procedures including physical examination, full and differential blood cell counts and 
serum biochemistry, computed tomography scan of the neck, chest and abdomen and a bone 
marrow biopsy had been negative, except for one case. this patient presenting with a solitary 
tumor on the head and involvement of only one draining lymph node was considered to be 
a primary cutaneous lymphoma and included in the C-ALCL group. Patients with LyP had not 
been staged, with a few exceptions. the group of secondary cutaneous ALCL included two 
patients with ALK-positive ALCL who developed skin lesions during follow-up, and six patients 
with ALK-negative ALCL who either presented with cutaneous and extensive extracutaneous 
localizations (n=4) or developing skin lesions during follow-up (n=2). A summary of the clinical 
and follow-up data of the different groups is presented in table 1.
Immunohistochemistry
Four-micrometre sections of formalin-fixed, paraffin-embedded tissues were put on APeS 
(3-aminopropyltriethoxysilane) slides (Sigma A-3648; Sigma, St Louis, MO, U.S.A.) and dried 
overnight (37°C). Sections were then dewaxed and rehydrated. endogenous peroxidase activity 
was blocked by incubation with 0.3% hydrogen peroxide in methanol. After antigen retrieval by 
boiling for 10 min in 10 mmol L-1 Citrate buffer (pH 6.0) for tRAF1, CD30, and BCL2 and in 1.0 mmol 
L-1 ethylenediaminetetraacetic acid (pH 9.0) for CD15 and MUM1, tissue sections were incubated 
overnight with antibodies against tRAF1 (1:20; Ber-tRAF1A antibody was kindly provided by Dr. 
Horst Dürkop, Dept. of Pathology, Charité, Berlin, Germany), CD30 (1:800), bcl-2 (1:400), CD15 
(1:100) and MUM1 (1:100) (DAKO, Glostrup, Denmark). Sections were then incubated with biotin-




Male 19 25 8 1 0
Female 8 14 3 1 6
Median age (range) 63 (41-86) 51 (7-84) 65 (37-87) 16 (11-24) 63 (19-87)
Median duration of follow-up, 
months (range)
63 (1-288) 65 (1-337) 78 (22-277) 70* (8-131) 49* (1-216)
Status at last follow-up:
- Alive without disease 13 8 3 1 1
- Alive with disease 6 29 3 0 1
- Died of lymphoma 6 0 4 1 3
- Died of other cause 2 2 1 0 1
*Median duration of follow-up from first skin lesions is 64 months (1 and 126 months, respectively); Sec., 
secondary
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labelled rabbit antimouse antibodies (1:200 e-0354), followed by incubation with peroxidase 
labeled streptavidin-biotin-complex (sABC-HRP; 1:100; K-0377 Dako). All secondary and tertiary 
antibodies were diluted in phosphate-buffered saline containing 1% bovine serum albumin for 
30 min at room temperature. Immunoreactivity was detected using diamino-benzidine (DAB)-
reagents and counterstaining was performed with Mayer’s haematoxylin (Klinipath, Duiven, 
the Netherlands). For confirmation of tRAF1 staining ten selected cases were also stained in 
the Dept. of Pathology, Centro Nacional de Investigaciones Oncológicas, Madrid, with the 
commercially available tRAF1 monoclonal antibody H3 (Santa Cruz, Heidelberg, Germany).
Immunostaining for tRAF1, Mum1, BCL2 and CD15 were semi-quantitatively scored as 
follows: - = no or less than 10% of tumor cells stained; ± = 10-50% of tumor cells stained; + = 
50-75% of tumor cells stained; ++ = more than 75% of tumor cells stained. 
Statistical evaluation
Statistical calculations were performed using SPSS 14.0 (SPSS Inc, Chicago, IL). Comparison of 
tRAF1, MUM1, BCL2 and CD15 expression between C-ALCL, LyP and MF-tR was performed using 
the Fisher’s exact test. All p-values were two-tailed. A p-value less than 0.5 was considered 
statistically significant. Comparison of prognosis between positive and negative cases of 
C-ALCL and MF-tR, respectively, was done using the Kaplan-Meier technique and log-rank 
testing. Disease-specific survival (DSS) was calculated from date of diagnosis until death from 
lymphoma or last follow-up without an event. For these purposes, patients with expression in 
more than 50% of tumor cells were considered as one group and compared with lymphomas 
containing less positive tumor cells or without expression in tumor cells.
ReSULtS
tRAF1
No significant differences were found in expression of tRAF1 between cases with C-ALCL, LyP 
and MF-tR (table 2). Clear cytoplasmic staining for tRAF1 in more than 50% of neoplastic cells 
was found in 20 of 23 (87%) cases with C-ALCL, 31 of 37 (84%) cases with LyP and eight of 11 
(73%) cases with MF-tR (Figure. 1). In only three of 23 (13%) C-ALCL cases, and three of 37 (8%) 
LyP cases, the neoplastic cells were completely negative for tRAF1, while scattered dendritic 
cells were tRAF1 positive, serving as an internal control. three cases of C-ALCL and two cases of 
LyP had been excluded, since both tumor cells and dendritic cells were completely negative for 
tRAF1. In one of the two ALK-positive ALCL ca. 40% of the neoplastic t-cells was tRAF1 positive, 
whereas four of six (67%) ALK-negative ALCL showed expression of tRAF1 in more than 50% of 
the neoplastic cells. the tumor cells of the PtL-NOS and plaque stage MF cases were consistently 
negative apart from few scattered positive cells, which correlated with CD30-positive cells 
in serial sections, and dendritic cells serving as an internal control (Figure. 2). Because of the 
discrepant results between the present study and previous studies6 a selection of ten biopsies 
of our series, including seven unequivocal positive or negative cases and three cases with in our 
hands questionable or at most very weak tRAF1 staining results were also stained in the Dept. 
of Pathology, Centro Nacional de Investigaciones Oncológicas, Madrid, with the commercially 
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Table 2. Overall positivity (%) and level of expression of TRAF1, MUM1, BCL2 and CD15 in 
four different groups of cutaneous CD30-positive lymphoproliferations.
C-ALCL LyP MF-TR
Sec cutaneous ALCL 
ALK+ ALK-
TRAF1
- 3 3 2 1 2 
± 0 3 1 1 0
+ 6 18 3 0 0 
++ 14 13 5 0 4
Overall positivity* 87% (20/23) 84% (31/37) 73% (8/11) 0% (0/2) 67% (4/6)
MUM1
- 0 0 0 0 0
± 0 3 0 0 0
+ 1 5 3 1 2
++ 17 9 6 0 3
Overall positivity* 100% (18/18) 82% (14/17) 100% (9/9) 100% (1/1) 100% (5/5)
BCL2
- 17 21 3 2 3 
± 4 4 0 0 0
+ 2 4 2 0 0
++ 4 10 6 0 3 
Overall positivity* 22% (6/27) 36% (14/39) 73% (8/11) 0% (0/2) 50% (3/6)
CD15
- 15 31 9 2 5 
± 0 1 1 0 0
+ 7 2 1 0 0
++ 5 5 0 0 1
Overall positivity* 44% (12/27) 18% (7/39) 9% (1/11) 0% (0/2) 17% (1/6)
- = complete negative or less than 10% of tumor cells stained; ± = 10-50% of tumor cells stained; + = 50-75% of 
tumor cells stained; ++ = more than 75% of tumor cells stained; 
Overall positivity: more than 50% of tumor cells stained.
available TRAF1 monoclonal antibody H3 (Santa Cruz, Heidelberg, Germany). Identical results 
were obtained in the seven unequivocal cases, while the three questionable cases of C-ALCL also 
showed TRAF1 expression in more than 80% of the CD30-positive tumor cells.
MUM1
There were no significant differences in the expression of MUM1 between C-ALCL, LyP and 
MF-TR (Table 2). Nuclear staining for MUM1 was found in more than 50% of tumor cells in all 
(100%) cases with C-ALCL, MF-TR and skin localizations of ALK-positive or ALK-negative ALCL. 







































Figure 1. Serial sections of a lymphomatoid papulosis skin biopsy (a-c) and a primary 
cutaneous anaplastic large cell lymphoma skin biopsy (d-f) showing haematoxylin and 









Figure 1. Serial sections of a lymphomatoid papulosis skin biop y (a-c) and a primary cutaneous 
anaplastic large cell lymphoma skin biopsy (d-f) showing haematoxylin and eosin staining (a;d) and 
positive staining for CD30 (b;e) and tRAF1 (c;f).
In LyP, MUM1 was expressed by more than 50% of the CD30-positive t-cells in 14 of 17 (82%), 
while in the other three cases approximately 40% of the neoplastic cells were MUM1 positive. 
None of the tumor cells in the PtL-NOS cases showed expression of MUM1 except for few 
scattered positive cells, which largely correlated with CD30-positive cells in serial sections.
BCL2 
Cytoplasmic staining for BCL2 in more than 50% of tumor cells was observed in six of 27 (22%) 
cases with C-ALCL, in 14 of 39 (36%) cases with LyP and in eight of 11 (73%) cases with MF-tR 
(table 2). In the group of secondary cutaneous ALCL, the tumor cells in the two ALK-positive 
ALCL cases were completely negative for BCL2, while BCL2 positivity was observed in three of 
Diagnostic markers in cutaneous CD30+ LPD
3
41
six (50%) ALK-negative ALCL cases. In all cases strong expression of BCL2 in reactive t-cells was 
observed. While there were no significant differences in BCL2 expression between C-ALCL and 
LyP, BCL2 expression was significantly higher in the group of MF-tR as compared to C-ALCL 
(p=0.008) and LyP (p=0.042).
CD15
Cytoplasmic and/or membranous staining for CD15 in more than 50% of tumor cells was 
observed in 12 of 27 (44%) cases with C-ALCL, seven of 39 (18%) cases with LyP and only one 
of 11 (9%) cases with MF-tR (table 2). In all cases strong cytoplasmic expression of CD15 in 
granulocytes was observed. In the group of secondary cutaneous ALCL, the two ALK-positive 
ALCL were completely negative for CD15, while CD15 was expressed by more than 50% of the 
tumor cells in one of six ALK-negative cases.
Prognostic significance
In the group of C-ALCL and the group of MF-tR, expression of BCL2 or CD15 by more than 50% of 
the neoplastic cells was not related to survival (data not shown). In C-ALCL, two of three (67%) 
tRAF1 negative cases died of lymphoma, in contrast to four of 20 (20%) tRAF1 positive cases 
(5-year DSS 0% vs. 93%; p=0.014).
DISCUSSION
In the present study we evaluated the diagnostic and prognostic significance of tRAF1, MUM1, 
BCL2 and CD15 expression in four groups of cutaneous CD30-positive lymphoproliferations. 
None of these markers were found to be a reliable diagnostic adjunct facilitating differentiation 






























Figure 2. Plaque-stage mycosis, with few CD30 positive tumor cells (a) and scattered 
CD1a-positive Langerhans cells (b). TRAF1 is expressed by (epi)dermal dendritic cells 




Figure 2. Plaque-stage mycosis, with few CD30 positive tumor cells (a) and scattered CD1a-positive 
Langerha s cells (b). tRAF1 is expressed by (epi)dermal dendritic cells (internal control), but not by 
the neoplastic t-cells (c).
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tRAF1 is an adaptor protein which is involved in intracellular signal transduction of several 
tNF receptor family members, including CD30.11 the exact function of tRAF1 is not clear. Previous 
studies showed that tRAF1 is strongly expressed in the neoplastic cells of classical Hodgkin 
lymphoma, but not by the CD30-positive tumor cells of systemic ALCL.11;12 In a recent study, Assaf 
et al. reported high tRAF1 expression in more than 80% of LyP cases, including cases showing 
cohesive sheets of CD30-positive large anaplastic cells (LyP, type C), while tRAF1 was expressed 
by only a small minority (7%) of primary and secondary cutaneous ALCL.6 they suggested that 
tRAF1 expression might be a valuable diagnostic marker for LyP, and speculated that activation 
of tRAF1 might play a role in the mechanism of spontaneous remission in this condition.
In the present study, using the same Ber-tRAF1A antibody, tRAF1 expression by more than 
50% of the neoplastic cells was found in roughly 70-80% of cases in all groups and no significant 
differences between LyP and C-ALCL were found. In contrast, cases of primary cutaneous PtL, 
NOS and plaque stage MF were consistently negative apart from few scattered positive cells, 
which correlated with CD30-positive cells in serial sections, and dendritic cells serving as an 
internal control.13 Because of the discrepant results between the present study and the study 
of Assaf et al,6 a selection of cases was also stained in a separate lab with the commercially 
available antibody H3 (Santa Cruz, Heidelberg, Germany), but staining with Ber-tRAF1A and 
H3 gave similar results. It should be noted that Assaf et al. used a cut-off point of more than 
80% for a positive staining, while in the present study 50% was taken as a cut-off point. taking 
staining of >75% as a cut-off point, the percentages of tRAF1 positive C-ALCL, LyP and MF-tR in 
our study were 61%, 35% and 45%, respectively (table 2), leaving the discrepant results between 
both studies unexplained. 
In the group of C-ALCL two of three tRAF1 negative cases died of lymphoma, in contrast 
to four of 20 (20%) tRAF1 positive cases. Although statistically significant, the small number of 
tRAF1 negative cases does not allow firm conclusions and further studies are required.
MUM1, also known as interferon regulatory factor-4 (IRF4) is a member of the interferon 
regulatory factor family of transcription factors. It was first identified in multiple myeloma, 
but is also expressed by plasma cells, activated t-cells, Hodgkin’s and Reed-Sternberg cells in 
classical Hodgkin lymphoma, and by the CD30-positive cells in systemic ALCL.14-17 Studies on 
MUM1 expression in primary cutaneous CD30-positive lymphoproliferations appeared only 
recently.7;9;18 Kempf et al. found MUM1 expression by neoplastic cells in 87% (13/15) of LyP cases 
(varying from 10-90%) and in only 20% (2/10) of C-ALCL cases (10% and 30%, respectively) and 
suggested that MUM1 expression may be a valuable tool for the distinction between LyP and 
C-ALCL. In contrast to this study, Wasco et al. found Mum1 expression by more than 50% of 
the cells in 63% (12/19) of LyP cases, in 80% (4/5) of C-ALCL cases, in 80% (4/5) of secondary 
cutaneous ALCL cases and in 100% (9/9) of MF-tR cases. Consistently, Feldman et al. reported 
MUM1 expression in 93% (13/14) of C-ALCL cases.18 In addition, these authors described the 
presence of a recurrent translocation involving the IRF4 gene in 57% (8/14) of C-ALCL cases. 
Also in our study expression of MUM1 by more than 50% of the neoplastic cells was found in 
70-100% of all four groups of cutaneous CD30-positive lymphoproliferations (table 2), while 
staining in PtL, NOS was restricted to few scattered positive cells which largely correlated with 
CD30-positive and/or tRAF1-positive cells in serial sections. taken together, these observations 
Diagnostic markers in cutaneous CD30+ LPD
3
43
suggest that both tRAF1 and MUM1 expression are closely associated with CD30 expression 
and are no useful diagnostic markers in the differentiation of cutaneous CD30-positive 
lymphoproliferations. this is further supported by the expression of tRAF1 by CD30-positive 
blast cells in patients with skin localizations of Hodgkin lymphoma, eBV-positive diffuse large 
B-cell lymphomas and a patient with Orf (data not shown). Moreover, recent gene expression 
profiling studies from our group showed increased levels of tRAF1 mRNA in skin biopsies from 
patients with C-ALCL and CD30-positive MF-tR as compared to skin biopsies of patients with 
PtL-NOS and CD30-negative MF-tR (van Kester, submitted).
In 1998 Paulli et al. reported lower levels of the anti-apoptotic protein BCL2 in LyP 
compared to nonregressing lesions of C-ALCL, and suggested that increased BCL2 
expression in nonregressing lesions of C-ALCL protects tumor cells from apoptosis. In our 
study, expression of BCL2 by more than 50% of the tumor cells was found in 36% of LyP cases 
and 22% of C-ALCL cases, which is consistent with percentages reported in other studies.19;20
Highest levels of BCL2 were expressed in MF-tR. It is tempting to speculate that high 
expression of this antiapoptotic protein in MF-tR contributes to treatment resistance and poor 
prognosis, but functional studies supporting such an assumption have not been performed.
CD15, also known as Lewis X, is a carbohydrate adhesion molecule, which is expressed 
on myeloid cells and mediates neutrophil adhesion and phagocytosis. In hematopathology, 
CD15 has been described as a useful marker to differentiate between ALCL (CD15 negative) 
and classical Hodgkin lymphoma (CD15 positive).21 However, the presence of CD15 in a 
varying number of tumor cells in ALCL is reported in small numbers of patients as well.3;21-23 
expression of Pax-5 (pan-B-cell marker) is a more reliable marker to differentiate between 
both conditions, since it is consistently negative in ALCL.24 During preparations for a slide 
seminar for cutaneous lymphomas we noticed two cases of C-ALCL which strongly expressed 
CD15. Since both of them had a fatal outcome, which is uncommon in C-ALCL, we wondered 
if CD15 expression was predictive of a poor survival in this group and decided to include CD15 
in the present study. Cytoplasmic and/or membranous CD15 staining in more than 50% of 
the neoplastic cells, was found in 18% of LyP cases and even in 44% of C-ALCL cases, but was 
not associated with a more unfavorable prognosis in the latter group. In contrast, CD15 was 
expressed in only one of eleven MF-tR cases. the results in C-ALCL and LyP are very similar to 
those of a French study, which reported CD15 positivity in a varying number of tumor cells in 2 
of 16 LyP cases and 6 of 25 C-ALCL cases.25 
In conclusion, the results of the present study suggest that expression of tRAF1, 
MUM1, BCL2 and CD15 can not be considered as useful diagnostic or prognostic markers in 
cutaneous CD30-positive lymphoproliferations. Differentiation between these different 
conditions in this group should always be based on a combination of clinical, histological and 
immunophenotypical criteria.
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Background: According to criteria of the World Health Organization-european Organization 
for Research and treatment of Cancer classification for cutaneous lymphomas a diagnosis 
of primary cutaneous CD30-positive anaplastic large cell lymphoma (C-ALCL) should be 
made only when systemic localizations have been excluded by adequate staging procedures, 
including a bone marrow biopsy. It has recently been questioned whether or not bone marrow 
examination should be performed routinely in indolent cutaneous lymphomas such as C-ALCL. 
Studies addressing this issue have never been performed.
Objectives: to determine the incidence of bone marrow involvement in patients with an ALCL first 
presenting in the skin to find out if the current policy to advice bone marrow examination should be 
maintained or whether a bone marrow biopsy should be performed only in selected cases. 
Methods: All patients presenting with skin lesions with histological and immunophenotypical 
features of an ALCL were retrieved from the database of the Dutch Cutaneous Lymphoma 
Group. Patients with a history of systemic ALCL and patients without bone marrow examination 
were excluded from the study. the final study group included 107 patients with an ALCL first 
presenting in the skin, who had been staged completely.
Results: Staging procedures showed the presence of extracutaneous disease in 20 patients, but 
bone marrow involvement was not detected in any of the 107 patients. Moreover, only one patient 
developed bone marrow involvement during follow-up (median follow-up period: 69 months)
Conclusions: Bone marrow examination has limited value in the staging of patients with an 
ALCL first presenting in the skin, and should be performed only in selected cases.




Primary cutaneous CD30-positive anaplastic large cell lymphoma (C-ALCL) is defined as a 
malignant lymphoma composed of large cells with an anaplastic, pleomorphic or immunoblastic 
cytomorphology and expression of the CD30 antigen by more than 75% of tumour cells.1 
Clinically, C-ALCL most often present with solitary or localized skin lesions; they may regress 
spontaneously, often relapse in the skin, but uncommonly disseminate to extracutaneous sites 
and have an excellent prognosis with a 10-year disease-specific survival (DSS) of approximately 
90%.2;3 Radiotherapy or, in cases of a small solitary tumour surgical excision are the preferred 
modes of treatment, while systemic chemotherapy is only required in exceptional cases.2 
C-ALCL must be differentiated from systemic ALCL involving the skin secondarily. these 
systemic ALCLs consist of lymphomas which are associated with the t(2;5) translocation 
resulting in expression of the anaplastic large cell lymphoma kinase (ALK) protein (ALK-positive 
ALCLs) and of lymphomas which are not (ALK-negative ALCLs).4;5 Importantly, C-ALCLs are not 
associated with the t(2;5) translocation and do not express ALK protein. Both ALK-positive and 
ALK-negative ALCL with secondary cutaneous involvement have a worse prognosis and require 
a completely different therapeutic approach as compared to C-ALCL.
According to the criteria of the World Health Organization-european Organization for 
Research and treatment of Cancer (WHO-eORtC) classification for cutaneous lymphomas a 
diagnosis of C-ALCL can only be made after adequate staging procedures have been conducted, 
including a bone marrow biopsy.1 Consistently, current guidelines of the Dutch Cutaneous 
Lymphoma Group (DCLG) require complete staging including a bone marrow biopsy.2 However, 
recent data from the registry of the DCLG show that in an increasing number of patients with 
an ALCL presenting in the skin, in particular those presenting with a solitary tumour that has 
resolved spontaneously or has been excised completely, staging is incomplete and particularly 
a bone marrow biopsy is not always performed. Moreover, in a recently published consensus 
paper from the International Society for Cutaneous Lymphomas (ISCL) and the european 
Organization of Research and treatment of Cancer (eORtC) Cutaneous Lymphoma Group, it was 
suggested that in indolent cutaneous lymphomas such as C-ALCL, bone marrow examination is 
recommended, but not required, unless indicated by other staging investigations.6 
Studies on the incidence of extracutaneous manifestations and, in particular, a positive 
bone marrow biopsy, in patients with an ALCL first presenting in the skin have never been 
published. In the present study, we therefore evaluated retrospectively the results of staging in 
a large group of such patients. the main purpose of this study was to determine the incidence 
of bone marrow involvement in these patients in order to find out if our current policy to advice 
bone marrow examination in all patients with an ALCL first presenting in the skin should be 
maintained or that a bone marrow biopsy should be performed only in selected cases.
PAtIeNtS AND MetHODS
All patients presenting with skin lesions with the histological and immunophenotypical features 
of an ALCL between 1986 and 2007 were retrieved from the database of the DCLG (n = 157). 
All cases in the Dutch registry have been reviewed by an expert panel of dermatologists and 
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hematopathologists before entry in this database. Moreover, for each patient in this database 
follow-up is collected yearly. these procedures guarantee that this initial study group did 
not contain patients with lymphomatoid papulosis or transformed mycosis fungoides, both 
of which may show histological features similar to a (C-)ALCL. From the initial group of 157 
patients, patients with a history of systemic ALCL who developed specific skin lesions during 
follow-up (n = 4) and patients without bone marrow examination (n = 46) were excluded from 
the study. the final study group consisted of 107 patients with an ALCL first presenting in the 
skin. Staging investigations had consisted of physical examination, full and differential blood 
cell count and serum biochemistry, computed tomographic scanning of chest and abdomen 
and other imaging studies if required, and a bone marrow biopsy. 
Statistical calculations were performed using SPSS 14.0 (SPSS Inc., Chicago, IL, U.S.A.). DSS 
and overall survival (OS) were calculated from date of diagnosis until death from lymphoma 
and death from any cause respectively, or last follow-up without an event. Survival curves were 
estimated using the Kaplan-Meier technique and comparison between curves was done by 
log-rank testing.
ReSULtS 
the median age at diagnosis of our final study group was 57 years (table 1). In total 72 patients 
were male (67%) and 35 patients were female (33%). Median follow-up was 69 months (range 
1-308 months). Staging investigations showed no evidence of extracutaneous disease in 87 
of 107 cases (81%), which were therefore classified as C-ALCL. In the remaining 20 patients 
staging was positive. In 11 of these 20 cases there was only involvement of peripheral lymph 
nodes draining a skin area containing ALCL lesions, suggesting that these were C-ALCLs with 
secondary lymph node involvement. the other nine patients showed more widespread disease 
with involvement of central lymph nodes and/or other extracutaneous localizations such as 
lung (three patients), central nervous system (two patients), bone (two patients), liver and 
spleen (one patient) and nasopharynx (one patient). Bone marrow involvement by ALCL was 
not observed in any of the 107 cases investigated. However, bone marrow biopsies showed 
B-cell chronic lymphocyic leukemia (B-CLL) in four cases (4%) and myelodysplastic syndrome 
in one case (1%). Patients with negative staging results and patients with positive staging results 
had a 5-year DSS of 90% and 51%, respectively (p = 0.001; Figure 1), whereas the 5-year OS was 
80% and 51%, respectively (p = 0.144).
DISCUSSION
the results of the present study indicate that bone marrow examination has limited clinical value 
in normal staging work-up of patients with an ALCL first presenting in the skin. Bone marrow 
involvement was not detected at the time of diagnosis in any of the 107 patients investigated, 
including 20 patients with extracutaneous disease at other sites. Moreover, in the database of the 
DCLG, which collects follow-up information for every included patient every year, bone marrow 
involvement during follow-up had only once been recorded. In this particular patient all staging 
investigations at diagnosis were negative, but six months after diagnosis involvement of multiple 
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peripheral lymph nodes, spleen, adenoid and bone marrow was observed. In addition, none of 
the 46 patients in whom bone marrow examination had not been performed initially, and who 
were therefore not included in the present study, had developed bone marrow involvement 
during follow-up. taken together, these observations indicate that bone marrow involvement 
is not or is rarely found in ALCL first presenting in the skin, and argue against bone marrow 
examination as an essential part of initial staging procedures. 
An unexpected finding in our study was the presence of a B-CLL in bone marrow biopsies 
of 4 of 107 patients. the coexistence of C-ALCL and B-CLL is uncommon with only few cases 
published.7;8 Several hypotheses exist for the coexistence of both t- and B-cell malignancies, 
including an origin from a common stem cell progenitor, exposure to carcinogens or viruses 
affecting oncogenes or tumour suppressor genes of both t- and B-cell precursors, and 
coincidental occurrence of two unrelated neoplasms.9
A limitation of the present study is that the results of bone marrow examinations were 
obtained from a database, and not by review of the original bone marrow specimens. Current 
guidelines for bone marrow evaluation request a biopsy specimen with a length of at least 
2 cm and with sufficient marrow fields, and in the case of doubtful infiltration additional 
immunohistochemistry.10 Consistently, in a study of ALK-positive ALCL, the incidence of bone 
marrow involvement increased from approximately 10% when only haematoxylin and eosin 
sections were analyzed, to 30%, when immunohistochemical stainings for CD30, epithelial 
membrane antigen and/or ALK were used.11 Considering the fact that our patients were collected 
during a period of 20 years, it cannot be excluded that our series contain a number of false-
negative marrows, as some biopsies from the early years might not meet current standards 
9
Figure 1. Survival curves of patients with an anaplastic large cell lymphoma first presenting in 
the skin with negative (n=87) and positive (n=20) staging results.
Figure 1. Survival curves of patients with an anaplastic large cell lymphoma first presenting in the skin 
with negative (n=87) and positive (n=20) staging results.
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and immunohistochemistry was not widely used at that time. However, no differences were 
observed between bone marrows included in the database before and after 2000, and we 
therefore believe that the number of false-negative bone marrows will be minimal, and will not 
significantly influence our conclusions. Moreover, even if we assume a small number of false-
negative bone marrows, the clinical consequences of not performing a bone marrow biopsy 
are expected to be minimal. It is of interest that the 5-year DSS and OS for the 46 patients in 
whom a bone marrow biopsy had initially not been performed were 95% and 72%, respectively, 
which is similar to that of the group of C-ALCL (Table 1). 
In conclusion, the results of the present study indicate that bone marrow examination has 
limited value in the staging of patients with an ALCL first presenting in the skin, and should be 
performed only in selected cases, such as patients with other positive staging assessments (e.g. 
involved lymph nodes) or rare patients requiring multiagent chemotherapy.
Table 1. Staging results and survival data of anaplastic large cell lymphomas first presenting in the skin, 
from the database of the DCLG.
Number 5-year DSS (OS)
Total number of patients with ALCL 157 -
History of non-cutaneous ALCL 4 -
Bone marrow not investigated 46 95% (72%)
Final study group 107 81% (74%)
Male:female 72:35 -
Median age , years (range) 57 (7-88) -
Median duration of follow-up, months (range) 69 (1-308) -
Staging negative 87 90% (80%)
Staging positive* 20 51% (51%)
Involvement of bone marrow 0 -
*Bone marrow involvement by B-CLL is not included in this category 
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Primary cutaneous anaplastic 
large cell lymphoma shows a 
distinct miRNA expression profile 
and reveals differences from 




MicroRNAs (miRNAs) are small non-coding RNA molecules that repress gene expression post-
transcriptionally. they may have oncogenic or tumor suppressing properties depending on 
their target genes. Although several studies have suggested that miRNAs are involved in the 
pathogenesis of cutaneous t-cell lymphoma (CtCL), the miRNA expression profile of primary 
cutaneous anaplastic large cell lymphoma (C-ALCL), an indolent type of CtCL, is not investigated.
In this study we analyzed the miRNA expression profiles of skin biopsies from 14 C-ALCL 
patients and 12 patients with benign inflammatory dermatoses (BID) by miRNA microarrays. 
We identified 13 miRNAs that are differentially expressed between C-ALCL and BID using 
ANOVA analysis (P<0.05, Benjamini-Hochberg corrected). Of these miRNAs the up-regulation 
of miR-155, miR-27b, miR-30c and miR-29b in C-ALCL was validated by miRNA-Q-PCR on 
independent study groups (C-ALCL and BID). 
In a second line of experiments the miRNA expression profiles of C-ALCL were compared 
with those of tumor stage mycosis fungoides (MF), a CtCL with less favorable prognosis. 
Although miRNA microarray analysis did not show statistically significant differences, miRNA-
Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, 
miR-93, miR-29b and miR-92a between tumor stage MF and C-ALCL.
this study, the first describing the miRNA expression profile of C-ALCL, reveals differences 
with tumor stage MF, suggesting a different contribution to the pathogenesis of these lymphomas.




Primary cutaneous anaplastic large cell lymphoma (C-ALCL) belongs to the group of CD30+ 
lymphoproliferative disorders, which is the second most common group of cutaneous t-cell 
lymphoma (CtCL). It is characterized by large cells with an anaplastic, pleomorphic, or 
immunoblastic cytomorphology and by expression of the CD30 antigen by more than 75% of 
the tumor cells 1. Although its histology indicates an aggressive lymphoma, C-ALCL often shows 
an indolent clinical behavior. It usually presents with solitary or localized skin lesions, which 
may regress spontaneously. Relapses in the skin occur frequently but extracutaneous disease 
is uncommon. C-ALCL patients have an excellent prognosis with a 10-year disease-specific 
survival (DSS) of approximately 90%2-4. the molecular mechanisms involved in the development 
of this disorder are largely unknown. 
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression 
post-transcriptionally. they are involved in crucial biological processes such as development, 
immune function, proliferation, apoptosis and the stress response5-7. there is increasing evidence 
that miRNAs are involved in the development of several types of cancers, including haematological 
malignancies8,9. Several studies have demonstrated specific miRNA expression profiles in different 
types of CtCL suggesting a role in the pathogenesis of these disorders10-14. Only one study focusing 
on the miRNA expression profiling of CtCL in general has included C-ALCL biopsies12. Hence the 
miRNA expression profile of C-ALCL is as yet unknown. 
to gain better insight in the molecular pathogenesis of C-ALCL, we determined the miRNA 
expression profile of C-ALCL compared to benign inflammatory dermatoses (BID) by miRNA 
microarray analysis and validated our results by miRNA-Q-PCR. 
In a second line of experiments we compared the miRNA expression profiles of C-ALCL 
with those of tumor stage mycosis fungoides (MF), a CtCL with a 10-year DSS of 42%15,16. 
the differences in miRNA expression described in this study suggest a different role in the 
pathogenesis of these lymphomas. 
MetHODS
Material selection
Formalin fixed paraffin embedded (FFPe) skin biopsies containing more than 75% of CD30+ 
large cells were selected from 21 C-ALCL patients, present in the database of the Dutch 
Cutaneous Lymphoma Group. In all cases the diagnosis had been confirmed by an expert 
panel of dermatologists and pathologists before entry in this database, using criteria of the 
WHO-eORtC classification1. the study group included 15 males and 6 females with a median 
age at the time of diagnosis of 62 years (range 33-83). Median follow-up period after diagnosis 
was 22 months (range 2-279). At last dates of follow-up 12 patients were alive with complete 
remission, four patients were alive with disease, two patients died of other causes and three 
patients died of disease. to assess the percentage of (tumor) cells in all biopsies, hematoxylin 
and eosin and CD3 stainings were reviewed, cut directly before and after slides sectioned for 
isolation. In total 14 biopsies were selected for array analysis and 7 additional biopsies were 
selected as a test group for validation by miRNA-Q-PCR. As a control group FFPe biopsies of 
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BID containing t-cell rich infiltrates were selected: 5 eczema and 7 lichen planus cases for array 
analysis and 5 additional eczema and 6 lichen planus cases for miRNA-Q-PCR. 
Results of miRNA microarray analysis of C-ALCL were compared with those recently 
published on 19 tumor stage MF10, that were generated using the same platform11. Both studies 
were performed in accordance with the Dutch code and Leiden University Medical Center 
guidelines on leftover material.
miRNA isolation
total RNA was isolated from 6x20 μm sections of C-ALCL biopsies and 8x20 μm sections of 
BID biopsies using the RecoverAll total Nucleic Acid Isolation Kit (Ambion, Warrington UK) 
according to the manufacturers’ protocol. 
miRNA array analysis
the complete miRNA profile of samples (3 μg total RNA) were elucidated using μRNA 
microarrays (containing complete human miRnome (miRBase 10.1)) as previously described10,17, 
using a synthetic human miRNA universal reference pool containing 454 miRNAs as a common 
reference. Image analysis was carried out using Bluefuse software (BlueGnome, Cambridge, 
UK). Raw fold ratio data were global loess-normalized within arrays and quantile normalized 
between arrays using the LIMMA package18. the normalized log ratios (average of four replicates 
per probe) were used for subsequent analysis in Genespring 7.2 (Agilent technologies, CA, US). 
MiRNAs that had a median intensity >300 fluorescence units background in more than 50% of 
the arrays were removed prior to ANOVA analysis. ANOVA analysis was performed to identify 
miRNAs differentially expressed between sample types and multiple testing correction was 
done using the Benjamini-Hochberg method.
MiRNA-Q-PCR
MiRNA cDNA synthesis and miRNA-Q-PCR was performed as described before10, using 300 ng 
RNA as input material for reverse transcription with the miRNA reverse transcription kit and 
the stem-loop Megaplex primer pool A v. 2.1 (Applied Biosystems, Nieuwerkerk a/d IJssel, the 
Netherlands). MiRNA-Q-PCR was performed using taqman miRNA assays and 2x Universal PCR 
mastermix (Applied Biosystems). All reactions were run on the LightCycler480 (Roche, Almere, 
the Netherlands), according to manufacturer’s protocol (Applied Biosystems). MiRNA expression 
levels were analyzed using the ∆Ct method expressed relative to U6. Statistical analyses were 
performed using the Mann-Whitney U-test in SPSS version 17.0 (SPSS Inc, Chicago, Illinois).
ReSULtS
We first determined the miRNA profiles from FFPe biopsies of 14 C-ALCL patients and 12 BID 
(eczema n  =  5 and lichen planus n  =  7) using miRNA microarrays (miRBase v.10.1). In total, 13 
miRNAs were statistically significantly differentially expressed between C-ALCL and BID with an 
adjusted p-value <0.05 (table 1). twelve of these miRNAs showed higher expression in C-ALCL 
and 1 miRNA showed lower expression in C-ALCL. Of the 12 higher expressed miRNAs, 5 had a 
fold-change (FC) higher than 2 (highest FC: 5.95). the only miRNA lower expressed in C-ALCL 
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was miR-197 (FC: -1.52). to validate these results, miRNA-Q-PCR was performed for miR-155, 
miR-29b, miR-30c and miR-27b in an additional group of C-ALCL (n = 7) and BID (eczema n = 5 
and lichen planus n  =  6). All miRNA-Q-PCR results are consistent with the microarray data, 
showing significant differential expression between C-ALCL and BID (P < 0.05; Figure 1A). 
Comparison of miRNA microarray results from C-ALCL with those from tumor stage MF, 
showed differential expression of several miRNAs, but none remained statistically significant 
after multiple testing correction. In line with these results the unsupervised cluster analysis, 
also including BID, was unable to classify the different disease entities into separate groups, 
although there was a tendency to cluster separately from BID (Figure 2). 
Although miRNA microarray analysis did not show statistically significant differences 
between C-ALCL and tumor stage MF, we noticed that the set of miRNAs discriminating 
C-ALCL from benign controls (this study) is different from the set discerning tumor stage MF 
from the same controls 10. We therefore extended the analysis of C-ALCL and used miRNA-
Q-PCR to determine the expression of miR-93, miR-92a, miR-30b, miR-16 and miR-383, which 
were differentially expressed between tumor stage MF and BID. except for miR-383, all miRNAs 
showed significant up-regulation in C-ALCL vs. BID (Figure 1B). In analogy, we also measured 
miR-29b and miR27b in tumor stage MF, using the validation set as described by van Kester et al.10, 
resulting in the up-regulation of miR-29b in tumor stage MF vs. BID (p < 0.01), while miR-27b is 
not differentially expressed (data not shown). Finally, we determined whether any of the miRNAs 
assayed by Q-PCR is differentially expressed between C-ALCL and MF. As depicted in Figure 3, 
this analysis identified differential expression of miR-155, miR-27b, miR-93, miR-92a and miR-29b.
Table 1. Differentially expressed miRNAs with chromosomal location 
miRNA Fold change Adj. P-value Chromosomal location
miR-197 -1,52 0,0443 1: 110141515-110141589 [+]
miR-15b 1,50 0,0443 3: 160122376-160122473 [+]
miR-20a 1,54 0,0463 13: 92003319-92003389 [+]
miR-342-3p 1,63 0,0443 14: 100575992-100576090 [+]
miR-146b 1,66 0,0443 10: 104196269-104196341 [+]
miR-26b 1,83 0,0443 2: 219267369-219267445 [+]
miR-17-5p 1,95 0,0413 13: 92002859-92002942 [+]
miR-27b* 1,95 0,0443 9: 97847727-97847823 [+]
miR-92b 2,09 0,0443 1: 155164968-155165063 [+]
miR-30c* 2,15 0,0413 1: 41222956-41223044 [+]
6: 72086663-72086734 [-]
miR-29b* 3,00 0,0443 7: 130562218-130562298 [-]
miR-155* 5,54 0,0035 21: 26946292-26946356 [+]
miR-425-5p 5,95 0,0443 3: 49057581-49057667 [-]
Positive fold changes are up regulated in C-ALCL samples and negative value is down-regulated compared to 
controls. Adj. P-value is adjusted P-value after Benjamini-Hochberg multiple testing correction. *validated











































































































































































































































































































In this study we evaluated the miRNA expression profile of C-ALCL with miRNA microarrays and 
miRNA-Q-PCR, by comparing C-ALCL with BID and tumor stage MF. Using miRNA microarrays, 
we found thirteen miRNAs differentially expressed between C-ALCL and BID, twelve up-
regulated and one down-regulated. We validated and confirmed expression of miRNA-155, 
miR-27b, miR-30c and miR-29b with miRNA-Q-PCR in two independent groups of C-ALCL and 
BID. Since miRNA deregulation in cancer is often correlated with DNA copy number alterations5,19, 
we subsequently compared the genomic location of differentially expressed miRNAs in C-ALCL 
with previous described copy number alterations. However, a correlation to genomic regions 
of gain could only be established for up regulation of miR-29b20-23. this suggests that other 
mechanisms such as transcriptional deregulation or epigenetic alterations probably are more 
important in deregulation of miRNA expression in C-ALCL19.
Since these array-based analyses of miRNA profiles of C-ALCL were performed using the 
same platform as the recently published experiments on miRNA profiling of tumor stage MF, 
a proper comparison (including normalisation and statistical analysis) was feasible10,11. Under 
stringent statistical conditions no differences between C-ALCL and MF were identified. However, 




Figure 2. Unsupervised cluster analysis C-ALCL, tumor stage MF and benign controles. Heatmap representing miRNA array 
expression data of C-ALCL samples (n=14, depicted in light blue), tumor stage MF samples (n=19, depicted in dark blue) and benign 































Figure 2. Unsupervised cluster analysis C-ALCL, tumor stage MF and benign controles. Heatmap 
representing miRNA array expression data of C-ALCL samples (n=14, depicted in light blue), tumor 
stage MF samples (n=19, depicted in dark blue) and benign controls (n=12, depicted in yellow).
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being differentially expressed between tumor stage MF or C-ALCL and BID) revealed not only 
further differences between the two disease entities (miR-155, miR-27b, miR-93, miR-92a and 
miR-29b) but also additional differences between C-ALCL and BID (miR-93, miR-92a, miR-27b, 
miR-30b and miR-16). We concluded that miRNA arrays are well suited for initial genome-wide 
screening, but apparently are less sensitive for detection of more subtle changes in miRNA 
expression. A similar observation was recently made by Ralfkiaer et al. in the course of their 
miRNA profiling studies for diagnostic markers of CtCL supporting the notion that PCR assays 
are more sensitive than miRNA microarrays12. 
Several of the aberrantly expressed miRNAs were previously also identified in other 
malignancies including lymphoma. For instance, miR-155 is known to play a role in immune 
responses and required for t-cell function7,24. It is also a well-known oncogene involved in 
several hematological malignancies such as systemic ALCL and CtCL (12,25). In some B-cell 
lymphoproliferative disorders it appears that higher expression of miR-155 correlates with 
disease severity and prognosis26. In contrast, we find higher expression of miR-155 in C-ALCL, 
having a far better prognosis than tumor stage MF. Differential expression of miR-155 between 
CtCL with a good and a bad prognosis was also observed in another study from our group, 
showing differential expression of the miR-155 precursor (BIC) being high in C-ALCL and low in 
PtL-NOS which have a worse prognosis23. 
Altered expression of miR-27b has been found in several malignancies such as breast 
cancer and neuroblastoma, but has not been described in relation to lymphoma so far27,28. 
Peroxisome proliferator-activated receptor γ (PPARγ) is one of the validated targets of miR-27b 
in cardiomyocytes and human macrophages29,30. Previously this receptor has been implicated 
in tumorigenesis31, although it remains debatable whether this receptor is stimulatory or 
inhibitory. yang et al. found that PPARγ is highly expressed in systemic ALCL cases and 
contributes to malignant t-cell survival32. It is tempting to speculate that in C-ALCL miR-27b by 
targeting of PPARγ might contribute to the relative favorable prognosis compared to systemic 
ALCL, although validation experiments for this hypothesis are warranted.
MiR-30c and miR-29b have been reported to be down regulated in ALK- systemic ALCL and 
ALK+ ALCL, respectively25. In contrast to this, we demonstrate up regulation for both miRNAs 
in C-ALCL, possibly relating to the different pathogenesis of these lymphomas. MiR-30c is 
considered a tumor suppressive miRNA, predicting sensitivity to treatment in different tumour 
types33. MiR-29b is part of the tumor suppressive miR-29a/b1 cluster located within the common 
fragile site FRA7H on chromosome 7q32.3. Feldman et al. showed that the t6;7 (p25.3;q32.3) in 
systemic ALK-negative ALCL was associated with up-regulation of miR-29b1, illustrating that 
this location is indeed susceptible for chromosomal changes34. MiR-29b can regulate the 
expression of the oncogenes MCL1, tCL1 and CDK6 and serves as a prognostic marker in mantle 
cell lymphoma35,36. As miR-29b functions as a tumour suppressive miRNA its higher expression in 
C-ALCL compared to tumor stage MF might play a role in its indolent clinical behaviour and is in 
agreement with the described low expression of MCL1 in C-ALCL37.
MiR-93 is previously described as an oncomir preventing apoptosis and promoting tumor 
growth38,39 and higher expression correlates with a poor prognosis in ovarian cancer40.On the 
other hand, miR-93 over expression is reported in ALK+ ALCL cell lines when compared to ALK- 
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systemic ALCL cell lines25, correlating to the better prognosis of ALK+ vs ALK- systemic ALCL. 
MiR-92a is part of the oncogenic miR-17-92 cluster, involved in many malignancies including 
lymphoma41. It was previously established that higher expression of miR-92a correlates with 
poor prognosis in several malignancies including human esophageal squamous cell carcinoma42 
and in small cell lung cancer43. 
In summary, we have determined the miRNA expression profile of C-ALCL compared to BID 
using miRNA microarrays and observed that more miRNAs appeared differentially expressed 
using miRNA-Q-PCR. the same was true for the comparison of C-ALCL with tumor stage MF. We 
therefore suspect that the real number of differentially expressed miRNAs of C-ALCL compared 
to BID or tumor stage MF might be higher then observed in this study, probably due to cross-
hybridization problems or a restricted dynamic range of miRNA microarrays. Moreover, miRNA 
microarrays are only capable of measuring the relative expression levels of known (annotated) 
miRNAs and hitherto unknown miRNAs might be differentially expressed between the different 
disease entities as well. these restrictions might be overcome in the future using techniques like 
next generation deep sequencing, though the limited availability of suitable (frozen) material 
with a high tumor cell content will remain a challenge. the current miRNA expression profile 
of C-ALCL and the differences compared to tumor stage MF provide a framework for further 
(functional) studies and may help to reveal the molecular pathogenesis of these lymphomas.
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Large cell transformation (LCt) in mycosis fungoides (MF) is generally associated with an 
aggressive clinical course and poor survival, requiring aggressive therapeutic approach. 
However, a proportion of cases may follow an indolent clinical course. to identify prognostic 
factors we analyzed the prognostic relevance of clinical, histologic, and immunophenotypical 
features in a large cohort of transformed MF patients, including, 75 patients with only skin 
lesions, 19 patients with LCt in skin and lymph nodes and 6 patients with LCt in lymph nodes 
only. Multivariate analysis of the total group showed that CD30 negativity, folliculotropic 
MF, extent of skin lesions and extracutaneous transformation were associated with reduced 
disease-specific survival (DSS) and, except for CD30 negativity and folliculotropic MF, also 
overall survival. In a multivariate analysis of 75 patients with only skin lesions at the time of LCt, 
CD30 negativity, folliculotropic MF and extent of skin lesions were independent parameters for 
both DSS and overall survival. Using the most discriminating parameters as a prognostic index, 
in both study groups differences in DSS between patients with 0-1 unfavorable prognostic 
factor(s) and ≥2 unfavorable prognostic factors were statistically significant (p<0.001). this 
prognostic index may be helpful in predicting prognosis and selecting the most appropriate 
treatment in patients with transformed MF.




Mycosis fungoides (MF) is the most common type of cutaneous t-cell lymphoma, clinically 
characterized by the slow progression from patches to plaques and in a proportion of patients 
to tumors. In a minority of patients dissemination to nodal sites, other extracutaneous sites, or 
both may occur. Although patients with early patch/plaque stage MF generally run an indolent 
course with a 10-year disease-specific survival (DSS) over 80%, patients developing skin tumors 
or extracutaneous disease have a reduced 10-year DSS of 42% and less than 20%, respectively.1,2 
Apart from clinical stage, large cell transformation (LCt) in MF has been associated with 
an aggressive clinical course and a poor survival.3-10 Most studies report a median survival 
between 2 and 36 months (table 1). Data on prognostic factors within these studies are however 
inconsistent and often conflicting and are probably related to the small size of the groups 
studied thus far (12-45 patients; median, 22 patients). evaluation of these previous studies is 
further hampered by the inclusion of not only patients with MF, but also variable numbers of 
patients with Sézary syndrome (SS) in 5 of 7 studies, and by the variable proportions (17%-92%) 
of patients with transformation at extracutaneous sites. 
Remarkably, in a recent study of 1502 patients with MF/SS, including 70 patients with 
transformed MF at the time of first diagnosis, the median survival was 8.3 years and the 5-year 
overall and DSSs were 63% and 65%, respectively.1 Although not described in much detail, these 
survival data suggests a much better prognosis of transformed MF than reported in all previous 
studies (table 1). 
to better define the prognosis and prognostic factors in patients with transformed MF, we 
evaluated the clinical, histologic, and immunophenotypical features of a large cohort of 100 
transformed MF patients. this study reveals independent prognostic factors and provides a 
prognostic index that may be helpful in the clinical management of patients with transformed MF. 
MetHODS 
Patient selection
One hundred and thirty patients with a diagnosis of transformed MF or a histologic diagnosis 
of (early) blastic transformation were retrieved from the cutaneous lymphoma database of the 
Leiden University Medical Center (LUMC). For each case clinical records, skin biopsies (2 to 
6 biopsies/case) and lymph node biopsies, if applicable, were reviewed. Hundred cases were 
included because they had clinical and histological features consistent with MF, and at least 
one biopsy showing LCt according to the criteria described previously: the presence of large 
t-cells exceeding 25% of the total lymphoid infiltrate or forming microscopic nodules.4 this 
study group did not contain cases with coexisting lymphomatoid papulosis (LyP) or primary 
cutaneous anaplastic large cell lymphoma (C-ALCL).
In a previous study no difference in survival was found between patients presenting with 
tumor stage MF (stage IIB) with or without LCt.11 For that reason 25 patients with stage IIB MF with 
LCt at first presentation, were compared with 27 patients presenting with stage IIB MF without 
LCt at first presentation, including 15 patients who developed LCt during follow-up and 12 
patients who did not meet the criteria of LCt and were therefore excluded from the main study.




All patients were classified according to the new criteria proposed by the International Society 
for Cutaneous Lymphomas and european Organization for Research and treatment of Cancer.12 
Staging included complete physical examination, blood cell count and chemistry; in most cases 
Ct scan of abdomen, chest, neck, and head (in cases of head lesions or head and neck lesions); 
and 1 or multiple skin biopsies. In all patients with clinically significant adenopathy a lymph 
node biopsy had been performed. 
For each patient the following clinical data were recorded: sex, age at diagnosis MF and 
age at diagnosis of LCt, duration of skin lesions before MF, clinical stage at diagnosis MF, time 
interval between MF and LCt, clinical stage at LCt, extent of skin tumors at the time of LCt, 
first treatment after LCt, result of treatment, duration of follow-up and survival status. For 
the first skin biopsy showing transformation folliculotropic MF and the percentage of large 
t-cells (nodules of large cells but < 25%, 25-75% or >75%) were recorded. Immunohistochemical 
stainings against t-cell antigens (CD2, CD3, CD4, CD5, CD8), B-cell antigens (CD20, CD79a), 
histiocytes (CD68) and CD30 were studied to determine the phenotype of the atypical cells, to 
differentiate large t-cells from admixed histiocytes, and to determine the percentage of large 
t-cells expressing CD30 (0-25%, 26-50%, 51-75% or >75%). In the MF stage IIB group without 
transformation only age, sex, folliculotropic MF, extent of skin lesions, duration of follow-up 
and survival status were recorded.
Prognostic factors
the following parameters were analyzed for their prognostic significance in transformed MF: sex, 
age at diagnosis of LCt (≤60 yrs vs >60 yrs), time interval between MF and LCt (≤24 months after 
diagnosis MF vs >24 months after diagnosis MF), clinical stage at the time of LCt, folliculotropic 
MF, CD30 expression by > than 50% of the neoplastic t-cells and the extent of skin tumors. extent 




LCT at first 
diagnosis
Stage at time LCT Median 
survival 
(months)IA-IIA IIB IV
Dmitrovsky8 12 0/12 (0%) 1/12 (8%) 11/12 (92%) 2
Salhany4 17 7/17 (41%) 6/17 (35%) 11/17 (65%) 12
Greer3 22 9/22 (41%) 9/22 (41%) 13/22 (59%) 12
Diamandidou7 26 9/26 (35%) 7/26 (27%) 10/26 (38%) 7/26 (27%) 19
Vergier9* 45 8/45 (18%) 2/45 (4%) 24/45 (53%) 20/45 (44%) 36
Barberio6* 17 2/17 (12%) 7/17 (41%) 7/17 (41%) 3/17 (18%) 27
Arulogun5 22 7/22 (32%) 3/22 (14%) 11/22 (50%) 7/22 (32%) 27
Agar1 70 70/70 (100%) NR NR NR 100
Present study* 100 42/100 (42%) 10 (10%) 65 (65%) 25 (25%) 24
MF: mycosis fungoides; LCt: large cell transformation ; NR: not reported. *Studies that included only patients 
with mycosis fungoides
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of skin lesions tumors was scored as solitary, regional (multiple skin lesions within 1 anatomic 
region) or generalized (multiple lesions in > one anatomic region). In a separate analysis of the 75 
patients who presented with only skin lesions at the time of transformation, the percentage of 
large t-cells (< 25% but clusters, 25-75% or >75%) was included in the analysis as well. 
Statistical analysis
All statistical calculations were performed using SPSS version 17.0 (SPSS Inc). DSS was calculated 
from the date of first biopsy showing LCt until death as result of lymphoma or date of last follow-
up. Overall survival (OS) was calculated from the date of first biopsy showing transformation 
until the patient’s death or date of last follow-up. Survival curves were estimated by the method 
of Kaplan and Meier and comparison between curves was done by log-rank testing. Univariate 
analysis of parameters with possible prognostic significance for DSS and OS was performed 
using Cox proportional hazards regression analysis. Factors significant at the 0.25 level in 
univariate analysis were included in a multivariate analysis model. In this model P values below 
0.05 were considered significant and all parameters included were categoric. 
ReSULtS 
Clinical characteristics and follow-up data 
the main clinical and histological characteristics and follow-up data of the 100 patients with 
transformed MF are summarized in table 2. the study group included 64 males and 36 females 
(male-female ratio, 1.8:1), with a median age at transformation of 68 years (range, 33-90 years). 
the median time between the initial biopsy-proven diagnosis of MF and transformation was 
10 months (range, 0-222 months). Forty-two patients had transformation at first presentation. 
the other 58 patients developed LCt 1 to 222 months (median, 44 months) after the diagnosis 
MF had been made. At the time of LCt, 75 patients had transformation only in skin lesions; 19 
patients had transformation in both skin and lymph nodes (n=19), in 2 of them also in bone 
marrow or tongue; and 6 patients had transformation only in lymph nodes, but not in concurrent 
skin lesions (stage IVA). Altogether, 10 patients had MF stage IB, 65 stage IIB, 24 stage IVA and 1 
patient stage IVB. Initial treatment after transformation, listed in table 2, resulted in a complete 
remission in only 18 of 100 patients; the remission was however generally short-lived. Median 
survival after transformation was 24 months (range, 1-235 months). DSS after 2, 5 and 10 years 
was 62%, 38% and 36%, respectively, and OS was 57%, 33% and 24%, respectively. 
Histopathologic and immunophenotypical features 
Biopsies from tumorous lesions generally showed a dense and diffuse infiltrate throughout the 
entire dermis, whereas the infiltrates in biopsies from patients with plaques stage (stage IB) 
disease were generally confined to the upper dermis. In this latter group, 3 patients showed 
a predominantly intraepidermal accumulation of large CD30+ (1 case) or CD30- (2 cases) 
t-cells simulating pagetoid reticulosis. However, the clinical presentation and the presence of 
part of these large blast cells in the superficial dermal compartment ruled out this diagnosis. 
In the majority of cases, the large cell population consisted of a mixture of large t-cells with 
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Table 2: Clinical and histological characteristics of 100 patients with transformed mycosis fungoides.
Males : Females 64 : 36
Median duration skin lesions before diagnosis MF (months; range) 33 (1-480)
Median interval between diagnosis MF and LCT (months; range) 10 (0-222)
Median age at diagnosis MF (range) 64 (29-90)
Median age at diagnosis MF with LCT (range) 68 (33-90)
Site of LCT
Only skin 75
Only lymph node 6
Skin + lymph node 19







Percentage of blast cells








First therapy after LCT
Local radiotherapy (2) 44
Total skin electron beam therapy 12
Polychemotherapy 28
Other (local steroids, excision, photochemotherapy, etc.) 16
Median duration follow-up after:
start skin lesions (months; range) 100 (15-640)
diagnosis MF (months; range) 54 (5-318)
transformation (months; range) 24 (1-235)
Current status
Alive without disease 6
Alive with disease 25
Continued on the next page
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cerebriform nuclei, blast cells with prominent nucleoli (T-immunoblasts), intermediate forms, 
and variable numbers of large anaplastic cells. Cases with a monotonous population of either 
large cerebriform cells without prominent nucleoli (n=3) or T-immunoblasts (n=4) or large 
anaplastic cells (n=8) comprising > 75% of the total lymphoid infiltrate were less commonly 
observed. In 31 cases the histologic (and clinical) features were consistent with the diagnosis of 
folliculotropic MF. The percentages of large T-cells of the total lymphoid population in the skin 
biopsies showing transformation are presented in Table 2. Immunophenotypic analysis showed 
that 70 cases had a CD3+CD4+CD8- T-cell phenotype, 7 cases a CD3+CD4-CD8+ T-cell phenotype, 
and 19 cases a CD3+CD4-CD8- T-cell phenotype. In 4 cases the phenotype could not be assessed. 
In many cases there was (partial) loss of 1 or more pan-T-cell antigens, whereas 4 cases showed 
aberrant expression of CD20, CD79a, or both. CD30 was expressed by > 75% of the large T-cells 
in 39 cases, by 50 to 75% in 8 cases, and between 5% and 20% in 8 cases. In the other 45 cases, 
CD30 staining was either completely negative or expressed by only very few (<5%) large T-cells.
Prognostic factors 
In the total group of patients (n=100), both univariate and multivariate analysis established 
that extent of skin lesions, extracutaneous transformation, negative staining for CD30 and 
folliculotropic MF were associated with a reduced DSS (Table 3). Further analysis showed that 
the difference in survival between stage IB versus IIB was not significant, but that the differences 
between stage IV versus IIB and stage IV versus combined stage IB and IIB were significant for 
DSS (P=0.048 and P=0.018, respectively). Multivariate analysis for OS showed that extent of skin 
lesions and extracutaneous transformation, but not folliculotropic MF and CD30 negativity, 
were independent parameters for reduced OS (Table 3). 
In the group with only transformation in skin lesions (stage IB-IIB; n=75) multivariate analysis 
showed that CD30 negativity, folliculotropic MF and extent of skin tumors were independent 
parameters for reduced DSS and OS (Table 4). Further analysis showed no significant differences 
between solitary and regional skin tumors or between regional and generalized skin tumors. 
However, patients with generalized skin tumors had a significantly worse DSS (P=0.005) and OS 
(P=0.002) compared with the combined group of solitary and regional skin tumors. DSS curves 
of all independent parameters in the total group of patients (n=100) and in the patients with 
only skin lesions and LCT (n=75) are shown in Figure 1.
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MF: mycosis fungoides; LCT: large cell transformation; FU: follow-up; DSS: disease specific survival; OS: overall 
survival; (1) CD30 expression by more than 50% of the cells was taken as prognostic factor for statistical analysis; 
(2) often combined with other skin directed therapies such as local steroids or photochemotherapy.
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2-yr 5-yr 10-yr HR (95% CI) P HR (95% CI) P 2-yr 5-yr 10-yr HR (95% CI) P HR (95% CI) P
Sex 0.418 0.980
Male 64 25 (1-235) 65 38 38 1 59 31 21 1
Female 36 20 (2-160) 56 38 32 1.3 (0.7-2.2) 54 37 30 1 (0.6-1.6)
Age 0.395 0.043 0.071
<60 years 34 42.5 (3-215) 70 40 40 1 70 40 36 1 1
≥60 years 66 19 (1-235) 57 38 33 1.3 (0.7-2.2) 47 29 16 1.7 (1.0-2.9) 1.9 (0.9-4.0)
Time interval between MF and LCT 0.089 0.322 0.246 0.475
≤24 months 63 30 (2-215) 71 44 39 1 1 66 36 25 1 1
>24 months 37 17 (1-235) 46 29 29 1.6 (0.9-2.7) 1.4 (0.7-2.5) 42 26 23 1.3 (0.8-2.2) 1.3 (0.7-2.3)
Clinical stage at LCT 0.021 0.046 0.224 0.002
Skin disease (stage IB+stage IIB) 75 26 (1-235) 69 44 44 1 1 59 36 26 1 1
Extracutaneous disease (stage IV) 25 20 (3-215) 42 23 17 1.9 (1.1-3.3) 1.9 (1.0-3.7) 42 23 17 1.4 (0.8-2.3) 3.2 (1.5-6.6)
CD30 expression 0.003 0.039 0.007 0.068
Positive 47 38 (1-215) 78 55 50 1 1 70 49 33 1 1
Negative 53 20 (2-235) 48 24 24 2.3 (1.3-4.1) 2.0 (1.0-3.7) 46 19 16 2.0 (1.2-3.2) 1.8 (1.0-3.3)
Folliculotropic MF 0.060 0.048 0.318
Absent 69 25 (1-235) 67 45 42 1 1 57 37 25 1
Present 31 22 (2-134) 52 25 25 1.7 (1.0-3.0) 1.9 (1.0-3.4) 50 24 24 1.3 (0.8-2.2)
Extent of skin lesions 0.005 0.034 0.002 0.023
Solitary 22 43 (5-164) 89 68 59 1 1 81 61 54 1 1
Regional 27 23 (1-235) 74 39 39 1.9 (0.8-4.9) 1.7 (0.7-4.4) 62 29 29 2.0 (0.9-4.5) 1.7 (0.6-4.4)
Generalized 45 20 (2-100) 46 23 . 3.6 (1.6-8.5) 3.0 (1.2-7.2) 44 20 . 3.5 (1.7-7.4) 3.2 (1.3-7.7)
MF: mycosis fungoides; LCT: large-cell transformation; DSS: disease specific survival; OS: overall survival; HR: 
Hazard ratio; Missing data: extent of skin lesions: 6.
Prognostic index 
Because patients may have a combination of favorable and unfavorable prognostic factors, 
we developed a prognostic index, that may better predict prognosis and be an useful tool 
in selecting appropriate treatment. For that purpose the most discriminating independent 
prognostic factors for DSS were selected. For the total group of patients with transformed MF 
these were the presence of generalized skin lesions, extracutaneous transformation, CD30 
negativity, and folliculotropic MF. Patients with 0 (16 cases), 1 (36 cases), 2 (31 cases), 3 (14 cases) 
or 4 (3 cases) unfavorable prognostic factors had a 2-year DSS of 83%, 85%, 52%, 14% and 33%, 
respectively. Sub analysis showed that the difference in DSS between the 52 patients with 0-1 
unfavorable prognostic factor and the 48 patients with 2 to 4 unfavorable prognostic factors 
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2-yr 5-yr 10-yr HR (95% CI) P HR (95% CI) P 2-yr 5-yr 10-yr HR (95% CI) P HR (95% CI) P
Sex 0.418 0.980
Male 64 25 (1-235) 65 38 38 1 59 31 21 1
Female 36 20 (2-160) 56 38 32 1.3 (0.7-2.2) 54 37 30 1 (0.6-1.6)
Age 0.395 0.043 0.071
<60 years 34 42.5 (3-215) 70 40 40 1 70 40 36 1 1
≥60 years 66 19 (1-235) 57 38 33 1.3 (0.7-2.2) 47 29 16 1.7 (1.0-2.9) 1.9 (0.9-4.0)
Time interval between MF and LCT 0.089 0.322 0.246 0.475
≤24 months 63 30 (2-215) 71 44 39 1 1 66 36 25 1 1
>24 months 37 17 (1-235) 46 29 29 1.6 (0.9-2.7) 1.4 (0.7-2.5) 42 26 23 1.3 (0.8-2.2) 1.3 (0.7-2.3)
Clinical stage at LCT 0.021 0.046 0.224 0.002
Skin disease (stage IB+stage IIB) 75 26 (1-235) 69 44 44 1 1 59 36 26 1 1
Extracutaneous disease (stage IV) 25 20 (3-215) 42 23 17 1.9 (1.1-3.3) 1.9 (1.0-3.7) 42 23 17 1.4 (0.8-2.3) 3.2 (1.5-6.6)
CD30 expression 0.003 0.039 0.007 0.068
Positive 47 38 (1-215) 78 55 50 1 1 70 49 33 1 1
Negative 53 20 (2-235) 48 24 24 2.3 (1.3-4.1) 2.0 (1.0-3.7) 46 19 16 2.0 (1.2-3.2) 1.8 (1.0-3.3)
Folliculotropic MF 0.060 0.048 0.318
Absent 69 25 (1-235) 67 45 42 1 1 57 37 25 1
Present 31 22 (2-134) 52 25 25 1.7 (1.0-3.0) 1.9 (1.0-3.4) 50 24 24 1.3 (0.8-2.2)
Extent of skin lesions 0.005 0.034 0.002 0.023
Solitary 22 43 (5-164) 89 68 59 1 1 81 61 54 1 1
Regional 27 23 (1-235) 74 39 39 1.9 (0.8-4.9) 1.7 (0.7-4.4) 62 29 29 2.0 (0.9-4.5) 1.7 (0.6-4.4)
Generalized 45 20 (2-100) 46 23 . 3.6 (1.6-8.5) 3.0 (1.2-7.2) 44 20 . 3.5 (1.7-7.4) 3.2 (1.3-7.7)
MF: mycosis fungoides; LCT: large-cell transformation; DSS: disease specific survival; OS: overall survival; HR: 
Hazard ratio; Missing data: extent of skin lesions: 6.
was statistically significant (P<0.001; Figure 2A). For the group of patients with only transformed 
skin lesions CD30 negativity, folliculotropic MF and the presence of generalized skin lesions 
were selected. Patients with 0 (14 cases), 1 (33 cases), 2 (21 cases) or 3 (7 cases) unfavorable 
prognostic factors had a 5-year DSS of 73%, 61%, 19% and 0%, respectively. The difference in DSS 
between the 47 patients with 0 to 1 unfavorable prognostic factor and the 28 patients with 2 to 3 
unfavorable prognostic factors was statistically significant (P<0.001; Figure 2B).
Comparison between patients with tumor stage MF (stage IIB) with or 
without transformation at first presentation.
Although transformed MF is generally associated with a poor prognosis, in a previous study 
no difference in survival was found between patients with stage IIB with or without LCT at the 
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Table 4: Univariate and multivariate analysis of prognostic factors in 75 transformed mycosis fungoides 














2-yr 5-yr 10-yr HR (95% CI) P HR (95% CI) P 2-yr 5-yr 10-yr HR (95% CI) P HR (95% CI) P
Sex 0.390 0.962
Male 51 27 (1-235) 73 46 46 1 60 36 22 1
Female 24 22.5 (2-160) 60 39 39 1.4 (0.7-2.7) 56 37 37 1 (0.6-1.9)
Age 0.515 0.084 0.012
<60 years 19 45 (4-164) 48 48 48 1 42 42 42 1 1
≥60 years 56 21 (1-235) 65 42 42 1.3 (0.6-2.8) 53 32 20 1.9 (0.9-3.7) 2.8 (1.8-6.1)
Time interval between MF and LCT 0.050 0.830 0.180 0.537
≤24 months 48 31 (2-164) 80 51 51 1 1 67 49 21 1 1
>24 months 27 20 (1-235) 51 31 31 2.0 (1.0-3.8) 1.1 (0.5-2.4) 45 27 22 1.5 (0.8-2.6) 1.2 (0.6-2.5)
Clinical stage at LCT 0.205 0.220 0.207 0.127
IB 10 48 (11-160) 77 64 64 1 1 77 64 38 1 1
IIB 65 25 (1-235) 68 40 40 2.2 (0.7-7.0) 2.2 (0.6-6.4) 57 32 25 1.8 (0.7-4.6) 2.1(0.8-5.6)
CD30 expression 0.008 0.006 0.026 0.027
Positive 36 38 (1-160) 90 57 57 1 1 76 50 33 1 1
Negative 39 21 (2-235) 54 33 33 2.6 (1.3-5.6) 3.2 (1.4-7.1) 45 24 21 1.9 (1.0-3.5) 2.1 (1.1-3.9)
Folliculotropic MF 0.014 <0.001 0.178 0.001
Absent 53 27 (1-235) 73 55 55 1 1 60 43 29 1 1
Present 22 23.5 (2-134) 61 22 22 2.3 (1.2-4.6) 4.0 (1.9-8.2) 58 21 21 1.5 (0.8-2.8) 3.4 (1.7-7.0)
% large cells in infiltrate 0.784 0.789
<25 (nodules) 7 26 (11-44) 100 . . 1 80 . . 1
25-75 32 27 (2-235) 71 49 49 0.67 (0.2-2.1) 60 41 29 0.74 (0.3-2.0)
>75 36 24.5 (1-164) 62 46 46 0.75 (0.2-2.2) 55 38 28 0.71 (0.3-1.9)
Extent of skin tumors 0.024 0.024 0.009 0.002
Solitary 19 30 (5-164) 87 69 69 1 1 78 62 62 1 1
Localized 22 29 (1-235) 84 49 49 1.6 (0.5-5.0) 1.2 (0.4-4.0) 69 35 35 1.7 (0.7-4.4) 0.9 (0.3-2.6)
Generalized 34 20.5 (2-100) 52 30 . 3.4 (1.3-9.5) 3.4 (1.2-9.7) 44 25 . 3.4 (1.5-7.8) 3.3 (1.3-8.0)
MF: mycosis fungoides; LCT: large-cell transformation; DSS: disease specific survival; OS: overall survival; HR: 
Hazard ratio
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Table 4: Univariate and multivariate analysis of prognostic factors in 75 transformed mycosis fungoides 














2-yr 5-yr 10-yr HR (95% CI) P HR (95% CI) P 2-yr 5-yr 10-yr HR (95% CI) P HR (95% CI) P
Sex 0.390 0.962
Male 51 27 (1-235) 73 46 46 1 60 36 22 1
Female 24 22.5 (2-160) 60 39 39 1.4 (0.7-2.7) 56 37 37 1 (0.6-1.9)
Age 0.515 0.084 0.012
<60 years 19 45 (4-164) 48 48 48 1 42 42 42 1 1
≥60 years 56 21 (1-235) 65 42 42 1.3 (0.6-2.8) 53 32 20 1.9 (0.9-3.7) 2.8 (1.8-6.1)
Time interval between MF and LCT 0.050 0.830 0.180 0.537
≤24 months 48 31 (2-164) 80 51 51 1 1 67 49 21 1 1
>24 months 27 20 (1-235) 51 31 31 2.0 (1.0-3.8) 1.1 (0.5-2.4) 45 27 22 1.5 (0.8-2.6) 1.2 (0.6-2.5)
Clinical stage at LCT 0.205 0.220 0.207 0.127
IB 10 48 (11-160) 77 64 64 1 1 77 64 38 1 1
IIB 65 25 (1-235) 68 40 40 2.2 (0.7-7.0) 2.2 (0.6-6.4) 57 32 25 1.8 (0.7-4.6) 2.1(0.8-5.6)
CD30 expression 0.008 0.006 0.026 0.027
Positive 36 38 (1-160) 90 57 57 1 1 76 50 33 1 1
Negative 39 21 (2-235) 54 33 33 2.6 (1.3-5.6) 3.2 (1.4-7.1) 45 24 21 1.9 (1.0-3.5) 2.1 (1.1-3.9)
Folliculotropic MF 0.014 <0.001 0.178 0.001
Absent 53 27 (1-235) 73 55 55 1 1 60 43 29 1 1
Present 22 23.5 (2-134) 61 22 22 2.3 (1.2-4.6) 4.0 (1.9-8.2) 58 21 21 1.5 (0.8-2.8) 3.4 (1.7-7.0)
% large cells in infiltrate 0.784 0.789
<25 (nodules) 7 26 (11-44) 100 . . 1 80 . . 1
25-75 32 27 (2-235) 71 49 49 0.67 (0.2-2.1) 60 41 29 0.74 (0.3-2.0)
>75 36 24.5 (1-164) 62 46 46 0.75 (0.2-2.2) 55 38 28 0.71 (0.3-1.9)
Extent of skin tumors 0.024 0.024 0.009 0.002
Solitary 19 30 (5-164) 87 69 69 1 1 78 62 62 1 1
Localized 22 29 (1-235) 84 49 49 1.6 (0.5-5.0) 1.2 (0.4-4.0) 69 35 35 1.7 (0.7-4.4) 0.9 (0.3-2.6)
Generalized 34 20.5 (2-100) 52 30 . 3.4 (1.3-9.5) 3.4 (1.2-9.7) 44 25 . 3.4 (1.5-7.8) 3.3 (1.3-8.0)
MF: mycosis fungoides; LCT: large-cell transformation; DSS: disease specific survival; OS: overall survival; HR: 
Hazard ratio
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time of first presentation.11 In our study, 65 patients had stage IIB at time of transformation. 
Within this group, 25 patients had LCT at first presentation. These 25 patients were compared 27 
patients with stage IIB MF without LCT at first presentation. Differences in DSS and OS between 
both groups were not statistically significant (Table 5). Further analysis between those patients 
who presented with stage IIB without LCT, but who developed LCT during follow-up (n=15) 
and those patients who did never develop LCT (n=12), also showed no statistically significant 
differences in survival (data not shown).
DISCuSSIOn 
Previous studies demonstrated that LCT in MF is associated with an aggressive clinical course and 
a poor survival.3-10 notwithstanding, in the past 20 years we have regularly seen MF patients with 
transformation in skin and even lymph node biopsies, who after treatment followed an indolent 
course for many years. This is reflected in the present study, in which 23 of 100 patients, including 
19 with LCT in the skin and 4 with LCT in lymph nodes, had an indolent course for 5 to almost 20 
years (median, 99 months; range, 60-235 months) after LCT. Only 4 of these 23 long-survivors 
died of lymphoma, 88 to 215 months after transformation. These observations underscore the 
need to define parameters that may help to predict which patients will have an aggressive and 
which a more indolent clinical course. Data on prognostic factors from previous studies are 
however conflicting, perhaps largely because of the small and heterogeneous groups studied. 
For that purpose we analyzed the clinical, histological, and immunophenotypical features of the 
largest cohort of transformed MF patients studied thus far. 
Figure 1. DSS curves of independent parameters in patients with transformed MF. (A) Curves for 
total group of patients with transformed MF (n=100), indicating CD30 expression, folliculotropic MF 
(FMF), extent of skin lesions, and clinical stage, respectively. (B) Curves for subanalysis of patients 
with only skin lesions and LCT (n=75), indicating CD30 expression, FMF and extent of skin lesions. 
*indicates number of persons at risk at the specified times after diagnosis of transformed MF.
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Figure 2. Prognostic index indicating differences in DSS. Prognostic index indicating differences in DSS 
in total group of patients with transformed MF (n=100; A) and in patients with only skin lesions and LCT 
(n=75;B). *indicates number of persons at risk at the specified times after diagnosis of transformed MF.
The median survival of the 100 patients was 24 months (range, 1-235 months) and the 5-year 
DSS and OS 38% and 33%, respectively. These results are similar to those of previous studies, 
(median survival, 12-36 months; 5-yr OS, 11%-32%), but contrast to those of Agar et al, who 
reported a median survival of 100 months and a 5-yr DSS and OS of 65% and 63%, respectively, 
in a group of 70 patients with LCT at first diagnosis.1 In this latter study, survival data and 
prognostic factors, including LCT, were analyzed on a group of 1502 patients with MF or SS.1 
Because further details on the group of 70 patients with LCT are not provided, the difference in 
survival between this recent study and all other studies in transformed MF cannot be explained. 
The most important prognostic factors in patients with transformed MF from the present 
and previous studies include advanced stage at transformation, CD30 expression, folliculotropic 
MF and increased extent of skin lesions. 
Advanced stage at transformation
Several studies reported that patients with extracutaneous transformation have a shorter 
median survival than patients with transformation limited to the skin.3,4 In contrast, in the study 
by Diamandidou et al, no difference in survival was found between patients with cutaneous and 
extracutaneous transformation.7 In fact, patients with transformed stage IIB (tumor stage) did as 
poorly as or even worse than patients with extracutaneous transformation (stage IV). Patients 
with transformed stage I-IIA (plaques) did significantly better than the combined transformed 
IIB-IV groups.7 In the present study, more advanced stage was significantly associated with 
reduced survival (Table 3). Subanalysis showed that extracutaneous transformation (stage IV) 
had a significantly poorer survival than cutaneous disease transformation (combined IB-IIB 
vs IV; P=0.018). no significant difference in survival was found between stage IB and stage IIB, 
indicating that extracutaneous transformation is the main factor responsible for shorter survival.
CD30 expression 
Several studies have suggested that CD30 expression in transformed MF may be associated with 
a better prognosis.5,6,9 However, in none of the published studies a significant difference between 
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CD30+ and CD30- cases was found, probably because of the small size of the study groups. In the 
present study, CD30 expression proved a strong and independent predictor of improved survival, 
both in the total group of patients and in patients with transformation limited to the skin. The 
favourable prognosis of the patients with CD30+ transformed MF raises the question whether part 
of them might not have a primary cutaneous CD30+ lymphoproliferative disorder (LyP of C-ALCL) 
coexisting with MF. Indeed differentiation between transformed MF and these primary cutaneous 
CD30+ lymphoproliferative disorder may be difficult, in particular in case the infiltrates contains 
>75% CD30+ blast cells, as observed in 39 of 100 cases (Table 2). However, none of our patients 
had a chronic recurrent self-healing papulonodular eruption consistent with LyP. In all CD30+ 
cases, a diagnosis of C-ALCL was unlikely, because 1) tumors developed in areas with pre-existent 
patches or plaques; 2) tumors showed an admixture with small- to medium-sized atypical T-cells 
with cerebriform nuclei (characteristic of MF); or 3) tumors showed significant folliculotropism, 
a condition that is rarely seen in cases of C-ALCL. Although it cannot be excluded, we do not 
believe our study contained patients with combined MF and C-ALCL. 
Folliculotropic MF 
The significance of folliculotropic MF in the prognosis of transformed MF has not been studied 
in previous studies. Although included as a distinct variant of MF in recent classifications for 
cutaneous lymphomas, cases of folliculotropic MF were included in the present study to allow 
comparison with previously published series. Both in the total group and in patients with 
Table 5. Summary of clinical characteristics and survival data of patients with tumor stage mycosis 
fungoides (stage IIB) with or without large cell transformation at presentation.
MF stage IIB with LCT 
 at presentation (n=25)
MF stage IIB without LCT 
 at presentation (n=27)
Male/Female 16 / 9 23 / 4
Median age (range) 72 years (42-90) 63 years (40-82) 
CD30 expression
- positive (>50% of blast cells)
- negative (<50% of blast cells)
13/25 (52%)
12/25 (48%) See footnote*
Folliculotropic MF 10/25 (40%) 13/27 (59%)
Extent of skin lesions
- solitary








Median survival (months) 42 (5-153) 53 (12-262)
2-yr DSS/OS 95% / 75% 88% / 84%
5-yr DSS/OS 56% / 40% 54% / 48%
10-yr DSS/OS 56% / 30% 29% / 16%
P-value DSS/OS 0.644 / 0.721
MF: mycosis fungoides; LCT: large-cell transformation; *in most cases scattered CD30+ blast cells (<1% to 5% of 
total infiltrate)
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transformation in only skin lesions, folliculotropic MF was a strong and independent predictor 
of reduced survival. Similarly, in other studies on large cohorts of MF patients folliculotropic MF 
was associated with a poorer survival.1,2 
Extent of skin tumors 
In the group with transformation only in skin lesions we investigated the prognostic significance 
of the extent of transformed skin lesions. It must be emphasized that transformation was 
generally demonstrated in only one lesion, assuming that other, clinically similar lesions, 
showed the same histology. The presence of generalized skin tumors was strongly associated 
with reduced DSS and OS, when compared with the combined group of solitary and localized 
skin tumors. However, no significant differences were found between solitary and localized 
skin tumors or between localized and generalized skin tumors. 
Percentage of blast cells
Progression from plaque- to tumor-stage MF is accompanied by a gradual increase of blast 
cells and a decrease of atypical T-cells with cerebriform nuclei and of inflammatory cells, and 
associated with a reduced prognosis. One might therefore expect that high percentages of 
blast cells (>75%), reflecting further tumor progression, are associated with a worse prognosis. 
However, no association between the percentage of blast cells and survival was found, 
consistent with the results of a previous study.9 Also, when stratified for CD30 expression, an 
association was not found (data not shown).
In conclusion, previous studies of transformed MF emphasized above all the aggressive 
clinical behavior and poor prognosis of these patients. As a result, recent national 
Comprehensive Cancer network guidelines suggest that a more aggressive therapeutic 
approach should be considered in patients with transformed MF compared to patients with 
the same stage of MF without LCT.14 However, some caution is warranted. First, consistent 
with previous studies we did not find a difference in survival between patients with stage IIB 
with or without LCT at first diagnosis.11,13There were no major differences in age, percentage 
of folliculotropic MF, and extent of skin lesions between both groups (Table 5). In fact, 
prognostic unfavourable factors (eg, folliculotropic MF, generalized skin lesions) were even 
slightly more frequent in the MF stage IIB group without LCT, strengtening our conclusions 
that MF stage IIB with LCT at presentation do not necessarily worse than MF stage IIB without 
LCT at presentation. This observation is important for clinical management, and suggests 
that patients with stage IIB with LCT should not be treated more aggressively than patients 
presenting with stage IIB without LCT, as suggested by recent national Comprehensive Cancer 
network guidelines.14 Second, although the median and 5-year survival in the present study 
were similar to that of previous studies, the results of this study clearly demonstrate that not all 
patients with transformed MF run an aggressive clinical course. The prognostic index described 
herein may be a valuable tool to predict which patients will have an aggressive and which a 
more indolent clinical course, and they may aid to select the most appropriate treatment in 
patients with transformed MF. However, the applicability and usefulness of this new tool needs 
to be validated by future studies. 
Prognosis of transformed mycosis fungoides
6
85
1. Agar nS, Wedgeworth E, Crichton S et al. Survival 
outcomes and prognostic factors in mycosis 
fungoides/Sezary syndrome: validation of the 
revised International Society for Cutaneous 
Lymphomas/European Organisation for 
Research and Treatment of Cancer staging 
proposal. J. Clin. Oncol. 2010;28:4730-4739.
2. van Doorn, Van Haselen CW, van Voorst Vader 
PC et al. Mycosis fungoides: disease evolution 
and prognosis of 309 Dutch patients. Arch. 
Dermatol. 2000;136:504-510.
3. Greer JP, Salhany KE, Cousar JB et al. Clinical 
features associated with transformation of 
cerebriform T-cell lymphoma to a large cell 
process. Hematol. Oncol. 1990;8:215-227.
4. Salhany KE, Cousar JB, Greer JP et al. Transformation 
of cutaneous T cell lymphoma to large cell 
lymphoma. A clinicopathologic and immunologic 
study. Am. J. Pathol. 1988;132:265-277.
5. Arulogun SO, Prince HM, ng J et al. Long-term 
outcomes of patients with advanced-stage 
cutaneous T-cell lymphoma and large cell 
transformation. Blood 2008;112:3082-3087.
6. Barberio E, Thomas L, Skowron F, Balme B, 
Dalle S. Transformed mycosis fungoides: 
clinicopathological features and outcome. Br. J. 
Dermatol. 2007;157:284-289.
7. Diamandidou E, Colome-Grimmer M, Fayad 
L, Duvic M, Kurzrock R. Transformation 
of mycosis fungoides/Sezary syndrome: 
clinical characteristics and prognosis. Blood 
1998;92:1150-1159.
8. Dmitrovsky E, Matthews MJ, Bunn PA et al. 
Cytologic transformation in cutaneous T 
cell lymphoma: a clinicopathologic entity 
associated with poor prognosis. J. Clin. Oncol. 
1987;5:208-215.
9. Vergier B, de Muret A, Beylot-Barry M et 
al. Transformation of mycosis fungoides: 
clinicopathological and prognostic features 
of 45 cases. French Study Group of Cutaneious 
Lymphomas. Blood 2000;95:2212-2218.
10. Diamandidou E, Colome M, Fayad L, Duvic 
M, Kurzrock R. Prognostic factor analysis in 
mycosis fungoides/Sezary syndrome. J. Am. 
Acad. Dermatol. 1999;40:914-924.
11. Vonderheid EC, Tam DW, Johnson WC, Van 
Scott EJ, Wallner PE. Prognostic significance 
of cytomorphology in the cutaneous T-cell 
lymphomas. Cancer 1981;47:119-125.
12. Olsen E, Vonderheid E, Pimpinelli n et al. 
Revisions to the staging and classification 
of mycosis fungoides and Sezary syndrome: 
a proposal of the International Society 
for Cutaneous Lymphomas (ISCL) and the 
cutaneous lymphoma task force of the European 
Organization of Research and Treatment of 
Cancer (EORTC). Blood 2007;110:1713-1722.
13. Cerroni L, Rieger E, Hodl S, Kerl H. 
Clinicopathologic and immunologic features 
associated with transformation of mycosis 
fungoides to large-cell lymphoma. Am. J. Surg. 
Pathol. 1992;16:543-552.
14. national Comprehensive Cancer network 
clinical practice guidelines (v.3.2011; available at: 
http://www.nccn.org/professionals/physician_
gls/PDF/nhl.pdf, accessed 18 May 2011).
REFEREnCES









the studies presented in this thesis focused on cutaneous CD30-positive lymphoproliferations, 
particularly on primary cutaneous anaplastic large cell lymphoma (C-ALCL). In recent 
classifications for malignant lymphomas C-ALCL is recognized as a distinct type of cutaneous 
t-cell lymphoma (CtCL). Characteristic clinical features of C-ALCL include presentation with 
solitary or localized skin lesions, tendency to spontaneous remission and in most patients an 
indolent course and excellent prognosis.
Although fairly well defined as a distinct type of CtCL, a number of controversies and 
outstanding questions remained, that needed to be addressed.
the main issues concerned:
1. the utility of recently described phenotypic markers in the differentiation between the 
different types of CD30-positive lymphoproliferations.
2. the lack of prognostic markers predictive of an unfavorable clinical course in a minority of 
patients with C-ALCL
3. the extent of staging procedures necessary to exclude systemic disease
4. molecular mechanisms underlying the favorable prognosis of C-ALCL
5. the prognostic significance of CD30 expression in transformed mycosis fungoides (MF).
In this final chapter, these issues are discussed on the basis of studies described in this 
thesis and data from literature.
Diagnostic value of phenotypical markers in cutaneous CD30-positive 
lymphoproliferations
Distinction between the different types of cutaneous CD30+ lymphoproliferations is important, 
as they have a different clinical behavior and require a different clinical approach. Since the 
histological and immunophenotypical features of these conditions show considerable overlap, 
clinicopathologic correlation is often required to differentiate between these disorders. However, 
this does not provide a definite diagnosis in all patients. For instance, in patients presenting with 
ALCL in the skin and regional lymph nodes, it may be difficult to differentiate between C-ALCL with 
secondary regional lymph node involvement and a secondary cutaneous ALCL. Differentiation 
may be facilitated by the use of phenotypical markers. Unlike systemic ALCL, most C-ALCL 
express the cutaneous lymphocyte antigen (CLA), but do not express epithelial membrane 
antigen (eMA) and anaplastic lymphoma kinase, which is indicative of the t(2;5) chromosomal 
translocation or variant translocations.1;2 Despite careful clinicopathologic correlation in some 
patients presenting with multifocal skin lesions, differentiation between LyP and C-ALCL may 
be impossible at first presentation. In such patients, designated as borderline cases, careful 
follow-up will normally disclose within weeks or months whether they have a waxing and 
waning eruption and can be labeled as LyP.3 Recent studies suggested that immunophenotypical 
markers like tRAF1, IRF4 (also known as MUM1) and BCL2 may be valuable diagnostic adjuncts 
in the differentiation between LyP and C-ALCL.4-7 Assaf et al. reported high tRAF1 expression in 
more than 80% of LyP cases, but in only 7% of cases of primary or secondary cutaneous ALCL.6 In 
another study, Kempf et al. described IRF4 (MUM1) expression by the neoplastic t-cells in 13 of 15 
(87%) cases of LyP, and in only 2 of 10 (20%) cases of C-ALCL.4 Wasco et al. did however not find a 




of the antiapoptotic protein BCL2 in LyP compared with nonregressing lesions of C-ALCL, and 
suggested that increased BCL2 expression in nonregressing lesions of C-ALCL protects tumor 
cells from apoptosis.7 Since the results of these studies are either unconfirmed or conflicting, 
in chapter 3 we evaluated the diagnostic value of these markers in a large group of cutaneous 
CD30+ lymphoproliferations, including these from 28 patients with C-ALCL, 39 patients with LyP, 
11 patients with CD30+ MF-tR, two with ALK+ ALCL and six with ALK- ALCL.
Both tRAF1 and IRF4 (MUM1) were found to be expressed by the CD30+ neoplastic t-cells in 
70-80% of LyP, C-ALCL and CD30+ MF-tR, which suggests that they are not useful to differentiate 
between these disorders. expression of BCL2 by > 50% of the tumor cells was found in 36% of LyP 
cases and 22% of C-ALCL cases, which also argues against diagnostic value in the differentiation 
between these disorders. Interestingly, highest levels of BCL2 were expressed in MF-tR. It is 
tempting to speculate that high expression of this antiapoptotic protein in MF-tR contributes 
to treatment resistance and poor prognosis, although functional studies supporting such an 
assumption have not been performed. In summary, tRAF1, MUM1 and BCL2 do not aid in the 
differentiation between different types of cutaneous CD30+ lymphoproliferations. 
Prognostic parameters in C-ALCL
While most C-ALCL patients have an excellent prognosis, risk factors that predict an unfavorable 
course, occurring in few patients with C-ALCL, are largely unknown. Several studies have 
suggested that age older than 60 years, absence of spontaneous remission, and presentation 
with multifocal skin lesions may correlate with reduced survival.8-11 Moreover, in recent studies 
extensive limb involvement and localization on the head and neck have been associated with 
a less favorable prognosis as well.12-14 In chapter 2 the potential prognostic significance of sex, 
age (≤60 vs. >60 years), extent of disease, site of presentation, and complete spontaneous 
remission of initial skin lesions was analyzed on a large group of 135 patients with C-ALCL. 
extent of disease was scored using the new tNM classification system for primary cutaneous 
lymphomas other than MF and Sézary syndrome, as proposed by the ISCL/eORtC.12 Because 
these patients by definition have no extracutaneous disease (N and M categories) at the time 
of diagnosis, only t categories were scored, as either t1 (solitary skin lesion), t2 (regional skin 
lesions) or t3 (generalized skin lesions).
Analysis of extent of skin lesions showed a 5-year disease-specific survival (DSS) of 93% for 
patients with t1 disease 93% for patients with t2 disease and 77% for patients with t3 disease, 
indicating that patients with t3 disease have a reduced, although statistically nonsignificant, 
survival rate compared with patients with t1 or t2 disease (P=.19). In addition, analysis of site 
showed a trend toward reduced 5-year DSS in patients with skin lesions on a leg, compared 
to localizations on other sites (82% for leg vs. 95% for head and neck, 96% for trunk, and 95% 
for arm; P=.23). Moreover, the 5-year DSS of patients with leg involvement (n=32) and patients 
without leg involvement (n=103) were 76% and 96%, respectively (P=.007; after adjustment for 
t category, P=.03). Sub analysis within the group of 18 patients with generalized skin lesions (t3 
disease) showed that those patients with involvement of one or both legs had a 5-year DSS of 
67% compared with 100% in patients without leg involvement (P=.20). Also, in the patients with 
regional skin lesions (t2 disease), leg involvement was associated with a reduced 5-yr DSS (76% 




patients with leg involvement. this is in line with other studies reporting on the poor prognosis 
of C-ALCL with extensive limb disease or leg involvement.12;14 Interestingly, also in other types 
of cutaneous lymphomas leg involvement has been associated with an aggressive clinical 
behavior. For instance, Poligone et al. described three patients with a CtCL localized to the 
lower leg and (locally) aggressive behavior, including two patients with tumor stage MF and 
one patient with peripheral t-cell lymphoma, not otherwise specified (PtL-NOS).15 Moreover, 
cutaneous lymphomas with the histological features of a diffuse large B-cell lymphoma located 
on the leg have a worse prognosis compared to primary cutaneous follicle centre lymphoma 
with a diffuse population of large B-cells located on the trunk or head, and have therefore been 
included as a separate entity (primary cutaneous large B-cell lymphoma of the leg or leg-type) 
in recent classifications for cutaneous lymphomas. the biological mechanism responsible for 
this poor prognosis is unclear. Cluster analysis of gene expression profiling data from C-ALCL 
patients showed that patients with extensive limb disease (including 5 samples from 3 patients) 
clustered separately from C-ALCL patients without extensive limb disease (including 9 samples 
from 7 patients).14 Among the upregulated genes in patients with extensive limb disease were 
StAt5 and IL2RA. the authors speculate that aberrant activation of the IL2R/StAt5 pathway may 
contribute to the more aggressive behavior of this subgroup of patients. A limitation of this 
study is the fact that validation experiments have not been performed. Moreover, as the group 
with extensive limb involvement included biopsies of only three patients, further studies are 
warranted to confirm these findings.
Apart from leg-involvement, other parameters investigated in this study were not 
significantly related to survival. For instance, the results of a previous study indicating that 
patients with skin lesions on the head or neck had a significant poor survival could not be 
confirmed.13 In that particular study, C-ALCL patients were retrieved from the Surveillance, 
epidemiology, and end Results (SeeR) database, which includes cases without independent 
histological review. It can therefore not be excluded that the SeeR cohort contains several 
patients with folliculotropic MF, which preferentially present at the head and neck region, 
commonly contain many CD30-positive blast cells and have a worse prognosis than patients 
with C-ALCL, as shown in chapter 6. 
In addition to the clinical parameters investigated in chapter 2, we also investigated the 
prognostic significance of immunophenotypical markers described in chapter 3, including 
tRAF1, BCL2 and CD15, in a group of 28 patients with C-ALCL. In C-ALCL, two of three tRAF1-
negative patients died of lymphoma, in contrast to four of 20 (20%) tRAF1-positive patients 
(5-year DSS 0% vs. 93%; P=.014). However, no difference in expression of BCL2 and CD15 was 
found between C-ALCL patients with a favorable prognosis and those who died of disease.
extent of staging procedures in C-ALCL
According to criteria of the WHO-eORtC classification for cutaneous lymphomas a diagnosis 
of C-ALCL should be made only when systemic localizations have been excluded by adequate 
staging procedures, including a bone marrow biopsy. Review of the database of the Dutch 
Cutaneous Lymphoma Group showed that bone marrow examination is often not performed, in 
particular in patients with a solitary tumor that has resolved spontaneously or has been excised 




primary cutaneous lymphomas suggests that in cutaneous lymphomas with an indolent clinical 
behavior, such as C-ALCL, bone marrow evaluation should be considered, but is not required 
unless indicated by other staging investigations.16
Since the incidence of bone marrow involvement in patients with an ALCL first presenting 
in the skin was not known, the study described in chapter 4 presents the staging results of 
107 patients with an ALCL first presenting in the skin. In 20 patients extracutaneous disease 
was found. eleven of these patients had involvement of peripheral lymph nodes, draining a 
skin area containing ALCL lesions, suggesting that these were C-ALCLs with secondary lymph 
node involvement. the other nine patients had more widespread disease with involvement of 
central lymph nodes and/or other extracutaneous localizations, suggesting systemic ALCL with 
secondary skin involvement. Bone marrow involvement by ALCL was never observed at the 
time of diagnosis and only one patient who had originally negative staging results, developed 
widespread systemic disease, including bone marrow involvement six months after diagnosis. 
In conclusion, the results indicate that bone marrow examination has limited value in the 
staging of patients with an ALCL first presenting in the skin, and should be performed only in 
selected cases. Obviously, in ALK+ ALCL cases presenting in the skin bone marrow examination 
should be included in the initial staging work-up, as ALK expression is indicative of a systemic 
(ALK+) ALCL which has (often subtle) bone marrow involvement in 10-30% of the cases.17
Molecular mechanisms underlying the favorable prognosis of C-ALCL
Although its histology indicates an aggressive lymphoma, C-ALCL usually shows an indolent 
clinical behavior. the molecular mechanisms responsible for this favorable prognosis are largely 
unknown. It has been suggested that interaction between CD30 and CD30L may contribute 
to apoptosis and the subsequent regression as observed in approximately 40% of the cases.18 
In addition, it has been speculated that increased expression of skin-homing chemokine 
receptors and CD30-mediated NF-kB activation may contribute to the pathogenesis of 
C-ALCL.19 Interestingly, two recent studies, using array-CGH analysis, showed that the 9p21 
deletion (involving the CDKN2A-CDKN2B gene locus), which was often found in MF-tR, was 
not or rarely observed in C-ALCL.20;21 Apart from genetic also epigenetic factors may play a 
role in the pathogenesis of C-ALCL. For instance, van Doorn et al. found that BCL7a was 
hypermethylated at a lower frequency in C-ALCL (14%) compared to aggressive (64%) CtCL 
entities and suggested that this gene functions as a tumor suppressor in lymphoid cells.22 
However little is known on histon modifications and miRNA expression in C-ALCL, which 
influence the epigenetic landscape as well. In chapter 5 we investigated the miRNA expression 
profile of C-ALCL. MicroRNAs (miRNAs) are small RNA species that regulate gene expression 
post-transcriptionally and are aberrantly expressed in many malignancies including lymphoma.
Using a genome wide approach (μRNA™ microarrays), we found 13 miRNAs differentially 
expressed between C-ALCL and benign inflammatory dermatoses (BID). Of these miRNAs the 
up-regulation of miR-155, miR-27b, miR-30c and miR-29b in C-ALCL was validated by miRNA-Q-
PCR on independent study groups of C-ALCL and BID. We also compared the miRNA expression 
profiles of C-ALCL with those of tumor stage MF.23 Although miRNA microarray analysis did not 
show statistically significant differences, miRNA-Q-PCR identified statistically significant higher 




stage MF. this observation is in line with the current insights that arrays should preferably be 
used as screening tools and are unable to detect more subtle differences.
In conclusion, the differences in miRNA expression of C-ALCL and tumor stage MF described 
in this study might reflect a different role in the pathogenesis of these lymphomas. 
this study illustrates two key limitations in the research on C-ALCL and CtCL in general. 
First of all, the limited availability of patient material with more than 70% of tumor cells, in order 
to avoid admixture of reactive lymphocytes. As a consequence the sample sizes for refined 
comparisons (e.g. C-ALCL with and without leg-involvement, or good versus poor prognosis) 
are too small for proper statiscal analysis. the same was true for additional comparisons between 
C-ALCL and tumor stage MF with transformation and CD30 expression (chapter 6). the second 
limitation relates to the fact that our study is purely descriptive with no (functional) data on any 
relevant miRNA target gene expression or dysregulation. Functional studies so far are hampered 
by the lack of suitable tools, e.g. animal models, which are available for other types of CtCL.24
the prognostic significance of CD30 expression in MF-tR
MF-tR is associated with an aggressive clinical course and a poor survival. Notwithstanding, in 
the past 20 years we have regularly seen MF-tR patients with transformation in skin and even 
lymph node biopsies who after treatment followed an indolent course for many years. this 
illustrates the need for parameters that help to predict which patients will have an aggressive 
and which a more indolent course and may help to select the most appropriate management 
for these patients. Given the excellent prognosis of C-ALCL (CD30+) compared to CtCL with a 
diffuse population of large CD30 negative neoplastic t-cells, one wonders whether also CD30+ 
MF-tR has a better prognosis than CD30 negative MF+tR.
In chapter 6 we therefore investigated the prognostic significance of CD30 expression and 
other clinical and histological parameters in a group of 100 MF-tR patients. Multivariate analysis 
of the total group showed that CD30 expression, folliculotropic MF, extent of skin lesions and 
extracutaneous disease were independent prognostic parameters for disease specific survival. 
In a multivariate analysis of 75 patients with only skin lesions at the time of transformation, 
CD30 expression, folliculotropic MF and extent of skin lesions were independent prognostic 
parameters for both DSS and OS. Using the most discriminating parameters as a prognostic 
index, in both study groups differences in DSS between patients with 0-1 unfavorable prognostic 
factor(s) and ≥2 unfavorable prognostic factors were statistically significant (P<.001). 
In summary, our analysis shows that CD30+ MF-tR has indeed a better prognosis. In 
particular, patients with CD30+ MF-tR presenting with a solitary tumor had a favorable prognosis 
(5-year DSS 68%). there is discussion whether such cases are MF-tR or MF with co-existent 
C-ALCL.14;15 In favor of CD30+ MF-tR above concurrent MF and C-ALCL are tumors developing 
in areas with pre-existent patches or plaques, showing an admixture with small to medium 
sized atypical t-cells with cerebriform nuclei (characteristic of MF) and/or showing significant 
folliculotropism, which is rarely seen in cases of C-ALCL. Notwithstanding, the differential 
diagnosis is difficult as illustrated by four patients in our study, that were first misclassified as 
C-ALCL. Retrospectively, one patient did present with concurrent patches and plaques which 
were not biopsied at the time of diagnosis, but the other three patients presented with solitary 




molecular mechanisms contribute to the favorable prognosis of CD30+ MF-tR and C-ALCL 
remains to be elucidated. It is tempting to speculate that CD30 itself, or more likely CD30-
CD30L interactions, is responsible for reduction of proliferation and even cell death, but CD30 
activation can also result in opposite effects. For instance, in Hodgkin lymphoma cell lines 
CD30-CD30L interactions may contribute to autocrine growth regulation, while in C-ALCL the 
same interactions may contribute to apoptosis.18 So far, CD30-CD30L interactions have not been 
studied in mycosis fungoides yet. Interestingly, the CDKN2A-CDKN2B deletion, which was often 
found in tumor stage MF, was associated with a lower survival rate.21,22 Additional analysis of the 
patients included in the study by van Doorn et al. on tumor stage MF showed that loss of 9p was 
never observed in the CD30+ cases and in 8 of the 14 (57%) CD30- cases. Similarly, loss of 9p21 is 
not observed in C-ALCL, compared to 50% of primary cutaneous PtL-NOS patients22. One could 
therefore speculate that the tumor suppressors within the CDKN2A-CDKN2B gene locus may 
contribute to the favorable prognosis of both C-ALCL and CD30+ MF-tR.
CONCLUSIONS AND PeRSPeCtIVeS
C-ALCL is a peculiar type of CtCL, as it combines a histology indicating an aggressive lymphoma 
with an excellent prognosis. Characteristic for its favorable clinical course is its tendency to 
spontaneous remission. the molecular mechanisms contributing to this spontaneous remission 
are largely unknown. Identifying these mechanisms is important as it might identify therapeutical 
targets, which can be used in the development of treatments not only for C-ALCL that do not 
show spontaneous regression, but potentially also for other types of aggressive CtCL. 
Because its expression in normal cells is limited, CD30 itself is an attractive molecule 
for targeted therapies. Recent studies using the SGN-30 monoclonal antibody have shown 
high response rates in patients with cutaneous CD30+ LPD.26 the results of a new anti-CD30 
monoclonal antibody coupled to the anti-tubulin agent monomethyl auristatin e (SGN-35; 
brentuximab vedotin) are even more impressive.27-30 In a phase II study of SGN-35 in patients 
with relapsed or refractory systemic ALCL 15 patients had skin lesions at the time of enrollment, 
while complete remission of skin lesions was found in 14 of them.29;30 Future studies should reveal 
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Non-Hodgkin lymfomen vormen een heterogene groep van aandoeningen die bestaan uit 
kwaadaardige woekeringen van witte bloedcellen. Ze ontstaan meestal in de lymfeklieren 
(nodaal), maar kunnen zich ook in andere organen presenteren (extranodaal). Primair cutane 
lymfomen (PCL) zijn non-Hodgkin lymfomen die zich in de huid (cutaan) presenteren, 
zonder dat er op het moment van diagnose aanwijzingen zijn voor lokalisaties elders in het 
lichaam. er zijn twee hoofdcategorieën: 75-80% zijn primair cutane t-cel lymfomen (CtCL) 
en 20-25%  primair cutane B-cel lymfomen (CBCL). Binnen de CtCL kunnen drie subgroepen 
worden onderscheiden: (1) de groep van klassieke CtCLs, waaronder mycosis fungoides (MF), 
varianten van MF en het Sézary syndroom (SS); (2) de groep van primair cutane CD30-positieve 
lymfoproliferatieve aandoeningen (CD30+ LPD); en (3) een groep van zeldzame en vaak 
agressieve cutane t/NK-cel lymfomen. 
een centraal onderwerp in dit proefschrift is het primair cutaan grootcellig anaplastisch t-cel 
lymfoom (C-ALCL). Dit lymfoom ziet er bij histopathologisch onderzoek onder de microscoop 
vaak agressief uit met velden grote ronde tumorcellen waarvan meer dan 75% het CD30 eiwit 
op zijn celmembraan tot expressie brengt. Patiënten met een C-ALCL presenteren zich meestal 
met solitaire of regionale huidafwijkingen, die in 20-40% van de gevallen de neiging hebben 
spontaan te verdwijnen (spontane remissie). Het beloop is doorgaans gunstig. De behandeling 
van persisterende afwijkingen bestaat meestal uit excisie of lokaal radiotherapie. Hoewel er 
frequent nieuwe afwijkingen in de huid kunnen ontstaan, vindt er maar zelden uitbreiding 
naar lokalisaties buiten de huid plaats. De ziektespecifieke 10-jaars overleving is dan ook 
ruim 90%. Het C-ALCL maakt samen met lymfomatoïde papulose (LyP) deel uit van de primair 
cutane CD30+ LPD. LyP wordt gekenmerkt door het komen en gaan van huidafwijkingen. 
Huidbiopten van beide aandoeningen vertonen bij histopathologisch onderzoek een aantal 
gemeenschappelijke kenmerken, waaronder expressie van het CD30 eiwit. 
Naast primair cutane CD30+ LPD zijn er ook andere aandoeningen, die CD30 tot expressie 
brengen. Voorbeelden zijn de systemische variant van het ALCL dat zich bij aanvang in 
de lymfklieren presenteert, maar zich op termijn (ook) kan uitbreiden naar de huid, een 
bepaald stadium van MF (getransformeerde MF) en verschillende reactieve (goedaardige) 
huidaandoeningen. Met histopathologisch onderzoek is het onderscheid tussen deze 
aandoeningen niet altijd goed te maken, terwijl dit wel relevant is, omdat de aandoeningen 
een ander klinisch beloop en een andere prognose hebben en vaak ook een andere 
behandeling vereisen. 
Ondanks dat in recente classificatie systemen voor cutane lymfomen het C-ALCL redelijk 
goed gedefinieerd is, bestonden er bij aanvang van dit promotietraject nog een aantal 
onduidelijkheden, zoals: 1) het nut van een aantal in de literatuur beschreven eiwitmarkers om 
het onderscheid te maken tussen verschillende soorten cutane CD30+ lymfoproliferaties; 2) 
het gebrek aan prognostische markers die voorspellend zijn voor het ongunstig beloop dat een 
klein deel van de patiënten met C-ALCL treft; 3) de uitgebreidheid van stageringsonderzoek, 
dat nodig is om lokalisaties buiten de huid vast te stellen; 4) de moleculaire mechanismen die 
verantwoordelijk zijn voor het gunstige klinisch beloop van de meeste patiënten met C-ALCL; 




Diagnostische waarde van bepaalde eiwitmarkers bij cutane CD30+ 
lymfoproliferaties
Recente studies hebben gesuggereerd dat de eiwitmarkers TRAF1, MUM1 (IRF4) en BCL2 
verschillend tot expressie worden gebracht op bepaalde cutane CD30+ lymfoproliferaties, 
en bij histopathologisch onderzoek van nut kunnen zijn om de verschillende typen te kunnen 
onderscheiden. Omdat de resultaten van deze studies nog niet bevestigd zijn door andere 
studies of elkaar tegenspreken, hebben we in hoofdstuk 3 de diagnostische waarde van deze 
markers in een grote groep van cutane CD30+ lymfoproliferaties onderzocht, waaronder 28 
patiënten met C-ALCL, 39 patiënten met LyP, 11 patiënten met CD30+ getransformeerde MF en 
8 patiënten met huidlokalisaties van de systemische variant van het ALCL. De resultaten van 
deze studie toonden aan dat TRAF1 en IRF4 niet nuttig waren om het onderscheid tussen de 
verschillende CD30+ lymfoproliferaties te maken omdat ze beide tot expressie werden gebracht 
in 70-80% van de gevallen van C-ALCL, LyP en CD30+ getransformeerde MF. Expressie van BCL2 
in meer dan 50% van de tumorcellen, werd gevonden in 36% van de LyP gevallen en in 22% van de 
C-ALCL gevallen, wat eveneens pleit tegen het nut ervan als diagnostische marker. Het bleek dat 
in CD30+ getransformeerde MF 73% van de gevallen BCL2 in meer dan 50% van de tumorcellen 
tot expressie bracht. Omdat dit eiwit celdood tegengaat, zou de hoge expressie ervan mogelijk 
een rol kunnen spelen bij de slechtere prognose van patiënten met een getransformeerde MF.
Prognostische factoren in C-ALCL
In hoofdstuk 2 hebben we in 135 C-ALCL patiënten de prognostische betekenis van een 
groot aantal factoren onderzocht, waaronder leeftijd, geslacht, uitgebreidheid van de 
huidafwijkingen, locatie en spontane remissie. Om de uitgebreidheid van de huidafwijkingen te 
scoren werd gebruik gemaakt van het Tumor, Node, Metastasis (TNM-) systeem, een systeem 
dat in gemodificeerde vorm al langer bestond voor MF en SS, maar pas recent is ontwikkeld voor 
andere PCL. Omdat deze patiënten op het moment van diagnose per definitie geen lokalisaties 
elders in het lichaam hebben, werd alleen het T-stadium gescoord, namelijk als T1 (solitaire 
huidafwijkingen), T2 (regionale huidafwijkingen) of T3 (gegeneraliseerde huidafwijkingen). Het 
bleek dat dit TNM-systeem goed toepasbaar was op patiënten met een C-ALCL. De analyse 
toonde verder aan dat patiënten met lokalisaties op één of beide benen, in tegenstelling tot 
lokalisaties elders op het lichaam, een significant slechter beloop hadden (ziektespecifieke 
5-jaars overleving van 76% versus 96%). Vervolgens werd er in de groep van patiënten met 
lokalisaties op één of beide benen een trend gezien dat patiënten met een T2 of T3 score een 
slechter beloop hadden dan patiënten met een T1 score (ziektespecifieke 5-jaarsoverleving 
voor T1 90%, versus 76% en 67%, respectievelijk voor T2 en T3). Het lijkt daarom verstandig 
deze patiënten goed te controleren tijdens de follow-up.
Uitgebreidheid van stagering bij patiënten met een ALCL in de huid
De diagnose van een PCL kan pas worden gesteld als lokalisaties buiten de huid zijn uitgesloten 
met behulp van stageringsonderzoek. Dit bestaat doorgaans uit een grondig lichamelijk 
onderzoek, bloedonderzoek, beeldvormend onderzoek (CT scan) en een beenmergbiopt. 




patiënten met een solitaire huidafwijking die spontaan verdwenen of volledig geëxcideerd is, in 
toenemende mate wordt afgezien van een beenmergbiopt. Omdat getallen over het voorkomen 
van beenmergbetrokkenheid bij patiënten met een ALCL in de huid echter niet bekend zijn, 
hebben we in hoofdstuk 4 de resultaten van beenmergonderzoek in 107 patiënten die volledig 
gestageerd waren, retrospectief geanalyseerd. Deze resultaten werden gecorreleerd met 
uitkomsten van overige stageringsonderzoeken (laboratorium- en beeldvormend onderzoek) en 
overlevingsdata. Bij 20 patiënten werden op het moment van diagnose ook lymfoomlokalisaties 
elders in het lichaam gevonden, echter het beenmerg bleek nooit betrokken. Bovendien 
ontwikkelde slechts één patiënt beenmergbetrokkenheid gedurende de follow-up. Deze 
patiënt had behalve beenmergbetrokkenheid ook lokalisaties van het lymfoom in verschillende 
lymfeklieren, de milt en de neusamandel. Deze studie toont aan dat het beenmergbiopt slechts 
een beperkte waarde heeft bij de stagering van patiënten die zich met een ALCL in de huid 
presenteren en dat een beenmergbiopt alleen overwogen hoeft te worden wanneer andere 
stageringsonderzoeken aanwijzingen geven voor lokalisaties van het lymfoom buiten de huid.
De moleculaire mechanismen verantwoordelijk voor het gunstige beloop 
van C-ALCL
Illustratief voor het klinisch gunstige beloop van C-ALCL is de neiging tot spontane remissie, 
dat bij 20-40% van de patiënten optreedt. Wanneer we de mechanismen kennen die hiervoor 
verantwoordelijk zijn, kunnen deze wellicht gebruikt worden als startpunt voor de ontwikkeling 
van geneesmiddelen voor patiënten zonder spontane remissie van de huidafwijkingen, zowel 
bij C-ALCL als andere agressieve CTCL. Recent is meer aandacht gekomen voor de rol van 
miRNAs bij de ontwikkeling van lymfomen. MiRNAs zijn kleine stukjes niet-coderend RNA die de 
expressie van genen kunnen reguleren. In hoofdstuk 5 hebben we daarom de miRNA expressie 
profielen in biopten van 14 C-ALCL patiënten onderzocht en vergeleken met 12 biopten van 
goedaardige ontstekingsziekten van de huid (benigne controles). We vonden significante 
verschillen in expressie van 13 miRNAs tussen C-ALCL en de benigne controles door gebruik te 
maken van miRNA microarrays, een platform waarmee in één keer heel veel (bekende) miRNAs 
tegelijkertijd onderzocht kunnen worden. Van deze miRNAs hebben we de verhoogde expressie 
van miR-155, miR-27b, miR-30c en miR-29b in C-ALCL ten opzichte van de benigne controles 
bevestigd op een onafhankelijke groep van 7 C-ALCL patiënten  en 11 benigne controles met 
een onafhankelijke techniek: miRNA-Q-PCR. We hebben de miRNA expressie profielen van 
C-ALCL ook vergeleken met die van 19 patiënten met tumor stadium MF, die uit een eerdere 
studie reeds bekend waren. Hoewel er tussen beide CTCLs met miRNA microarrays geen 
significante verschillen werden gevonden, werd er met miRNA-Q-PCR een significant hogere 
expressie van miR-155, miR-27b, miR-93, miR-29b en miR-92a gevonden in C-ALCL ten opzichte 
van tumor stadium MF. Dit toont aan dat microarrays goed gebruikt kunnen worden als een 
screenende techniek, maar voor het identificeren van subtiele verschillen in expressie tussen 
bepaalde lymfomen tekort kunnen schieten. In het algemeen zouden de verschillen in miRNA 
expressie tussen C-ALCL en tumor stadium MF op een verschillende rol in de pathogenese 
van deze CTCLs kunnen wijzen en gebruikt kunnen worden als uitgangspunt voor functionele 




De prognostische betekenis van CD30 expressie bij patiënten met 
getransformeerde MF
Het merendeel van de patiënten met MF heeft een klinisch beloop dat gekenmerkt wordt 
door de langzame ontwikkeling van oppervlakkige eczemateuze huidafwijkingen (patches) 
die langzaam steeds dikker worden (plaques). een klein deel van de patiënten ontwikkelt op 
termijn ook tumoren en lokalisaties buiten de huid. er kunnen zich gedurende deze ziekte ook 
op cellulair niveau veranderingen voordoen zoals blastaire transformatie van de kwaadaardige 
witte bloedcellen. In de literatuur spreekt men van blastaire transformatie bij MF indien bij 
histologisch onderzoek het infiltraat meer dan 25% blasten bevat. Blastaire transformatie bij 
MF is geassocieerd met een agressief klinisch beloop en een slechte prognose. De blastaire 
tumorcellen kunnen al dan niet CD30 tot expressie brengen. Vanwege de gunstige prognose 
van C-ALCL, waarbij CD30 expressie het belangrijkste kenmerk is,  hebben wij in hoofdstuk 
6 retrospectief de prognostische betekenis van CD30 expressie bij 100 patiënten met 
getransformeerde MF onderzocht. Daarnaast hebben wij de prognostische waarde van andere 
factoren onderzocht die in de literatuur gesuggereerd worden, maar vaak niet hard gemaakt 
konden worden vanwege te kleine patiëntengroepen. Patiënten met getransformeerde MF 
bleken inderdaad een ongunstig klinisch beloop te hebben met een ziektespecifieke 5-jaars 
overleving van 38%. In de 75 patiënten met alleen huidafwijkingen op het moment van 
transformatie bleken CD30 negativiteit, folliculotropie en uitgebreide(re) huidafwijkingen 
significant gecorreleerd met een slechtere prognose. Voor de volledige studiegroep van 100 
patiënten betrof dit dezelfde factoren en tevens lokalisaties met transformatie buiten de huid. 
Het bleek dat patiënten met 0-1 prognostisch ongunstige factor(en) een significant betere 
overleving lieten zien dan patiënten met 2 of meer prognostisch ongunstige factoren. Dit 
gegeven kan gebruikt worden om een prognose van patiënten met getransformeerde MF te 





Benner MF and Willemze R. bone marrow examination has limited value in the staging of 
patients with an anaplastic large cell lymphoma first presenting in the skin. Retrospective 
analysis of 107 patients. british Journal of Dermatology, 2008; 159(5):1148-1151.
Benner MF, Jansen pM, Meijer cJLM, Willemze R. Diagnostic and prognostic evaluation 
of phenotypic markers tRaf1, MuM1, bcL2 and cD15 in cutaneous cD30-positive 
lymphoproliferative disorders. british Journal of Dermatology, 2009; 161(1):121-127.
Benner MF and Willemze R. applicability and prognostic value of the new tnM classification 
system in 135 patients with primary cutaneous anaplastic large cell lymphoma. archives of 
Dermatology, 2009; 145(12):1399-1404.
van Kester Ms, ballabio E, Benner MF, chen XH, saunders nJ, van der fits L, van Doorn R, 
Vermeer MH, Willemze R, tensen cp, Lawrie cH. MiRna expression profiling of mycosis 
fungoides. Molecular oncology, 2011; 5(3):273-280.
Benner MF, Jansen pM, Vermeer MH, Willemze R. prognostic factors in transformed mycosis 
fungoides: a retrospective analysis of 100 cases. blood, 2012; 119(7):1643-1649.
Benner MF, ballabio E, van Kester Ms, saunders nJ, Vermeer MH, Willemze R, Lawrie cH, tensen 
cp. MiRna expression profiling of primary cutaneous anaplastic large cell lymphoma shows 





aCGH   Array-based comparative genomic hybridization
ALCL   Systemic anaplastic large cell lymphoma
ALK   Anaplastic lymphoma kinase
BCL2   B-cell CLL/lymphoma 2
BCL7a   B-cell CLL/lymphoma 7A
BID   Benign inflammatory dermatoses
C-ALCL   Primary cutaneous anaplastic large cell lymphoma
CBCL   Primary cutaneous B-cell lymphoma
CD30+ LPD  CD30+ lymphoproliferative disorders
CLA   Cutaneous lymphocyte antigen
CtCL   Primary cutaneous t-cell lymphoma
DCLG   Dutch Cutaneous Lymphoma Group
DSS   Disease-specific survival
eBV   epstein-Barr virus
eMA   epithelial membrane antigen
eORtC   european Organization for Research and treatment of Cancer
FC   Fold-change
FFPe   Formalin fixed paraffin embedded
HIV   Human immunodeficiency virus
HSV   Herpes simplex virus
IFN   Interferon
IRF4   IFN regulatory factor 4
ISCL   International Society for Cutaneous Lymphomas
LCt   Large cell transformation
LyP   Lymphomatoid papulosis
MF   Mycosis fungoides
MF-tR   transformed mycosis fungoides
miRNA   MicroRNA
MtX   Methotrexate
MUM1   Multiple myeloma antigen 1
NPM   Nucleophosmin
PPARγ   Peroxisome proliferator-activated receptor γ
PtL-NOS   Peripheral t-cell lymphoma, not otherwise specified
PUVA   Psoralen Ultra-Violet A
Rt   Radiotherapy
SS   Sézary syndrome
tGF-beta   transforming growth factor-beta
tNM   tumor, Node, Metastasis
tRAF1   tumor necrosis factor receptor associated factor 1
VZV   Varicella-Zoster virus
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